1
|
González-Moreno L, Santamaría-Cano A, Paradela A, Martínez-Chantar ML, Martín MÁ, Pérez-Carreras M, García-Picazo A, Vázquez J, Calvo E, González-Aseguinolaza G, Saheki T, del Arco A, Satrústegui J, Contreras L. Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver. Mol Genet Metab Rep 2023; 35:100967. [PMID: 36967723 PMCID: PMC10031141 DOI: 10.1016/j.ymgmr.2023.100967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Accepted: 03/10/2023] [Indexed: 03/18/2023] Open
Abstract
The deficiency of CITRIN, the liver mitochondrial aspartate-glutamate carrier (AGC), is the cause of four human clinical phenotypes, neonatal intrahepatic cholestasis caused by CITRIN deficiency (NICCD), silent period, failure to thrive and dyslipidemia caused by CITRIN deficiency (FTTDCD), and citrullinemia type II (CTLN2). Clinical symptoms can be traced back to disruption of the malate-aspartate shuttle due to the lack of citrin. A potential therapy for this condition is the expression of aralar, the AGC present in brain, to replace citrin. To explore this possibility we have first verified that the NADH/NAD+ ratio increases in hepatocytes from citrin(-/-) mice, and then found that exogenous aralar expression reversed the increase in NADH/NAD+ observed in these cells. Liver mitochondria from citrin (-/-) mice expressing liver specific transgenic aralar had a small (~ 4-6 nmoles x mg prot-1 x min-1) but consistent increase in malate aspartate shuttle (MAS) activity over that of citrin(-/-) mice. These results support the functional replacement between AGCs in the liver. To explore the significance of AGC replacement in human therapy we studied the relative levels of citrin and aralar in mouse and human liver through absolute quantification proteomics. We report that mouse liver has relatively high aralar levels (citrin/aralar molar ratio of 7.8), whereas human liver is virtually devoid of aralar (CITRIN/ARALAR ratio of 397). This large difference in endogenous aralar levels partly explains the high residual MAS activity in liver of citrin(-/-) mice and why they fail to recapitulate the human disease, but supports the benefit of increasing aralar expression to improve the redox balance capacity of human liver, as an effective therapy for CITRIN deficiency.
Collapse
|
2
|
del Arco A, González-Moreno L, Pérez-Liébana I, Juaristi I, González-Sánchez P, Contreras L, Pardo B, Satrústegui J. Regulation of neuronal energy metabolism by calcium: Role of MCU and Aralar/malate-aspartate shuttle. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2023; 1870:119468. [PMID: 36997074 DOI: 10.1016/j.bbamcr.2023.119468] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 03/17/2023] [Accepted: 03/21/2023] [Indexed: 03/30/2023]
Abstract
Calcium is a major regulator of cellular metabolism. Calcium controls mitochondrial respiration, and calcium signaling is used to meet cellular energetic demands through energy production in the organelle. Although it has been widely assumed that Ca2+-actions require its uptake by mitochondrial calcium uniporter (MCU), alternative pathways modulated by cytosolic Ca2+ have been recently proposed. Recent findings have indicated a role for cytosolic Ca2+ signals acting on mitochondrial NADH shuttles in the control of cellular metabolism in neurons using glucose as fuel. It has been demonstrated that AGC1/Aralar, the component of the malate/aspartate shuttle (MAS) regulated by cytosolic Ca2+, participates in the maintenance of basal respiration exerted through Ca2+-fluxes between ER and mitochondria, whereas mitochondrial Ca2+-uptake by MCU does not contribute. Aralar/MAS pathway, activated by small cytosolic Ca2+ signals, provides in fact substrates, redox equivalents and pyruvate, fueling respiration. Upon activation and increases in workload, neurons upregulate OxPhos, cytosolic pyruvate production and glycolysis, together with glucose uptake, in a Ca2+-dependent way, and part of this upregulation is via Ca2+ signaling. Both MCU and Aralar/MAS contribute to OxPhos upregulation, Aralar/MAS playing a major role, especially at small and submaximal workloads. Ca2+ activation of Aralar/MAS, by increasing cytosolic NAD+/NADH provides Ca2+-dependent increases in glycolysis and cytosolic pyruvate production priming respiration as a feed-forward mechanism in response to workload. Thus, except for glucose uptake, these processes are dependent on Aralar/MAS, whereas MCU is the relevant target for Ca2+ signaling when MAS is bypassed, by using pyruvate or β-hydroxybutyrate as substrates.
Collapse
|
3
|
Pérez-Liébana I, Juaristi I, González-Sánchez P, González-Moreno L, Rial E, Podunavac M, Zakarian A, Molgó J, Vallejo-Illarramendi A, Mosqueira-Martín L, Lopez de Munain A, Pardo B, Satrústegui J, Del Arco A. A Ca 2+-Dependent Mechanism Boosting Glycolysis and OXPHOS by Activating Aralar-Malate-Aspartate Shuttle, upon Neuronal Stimulation. J Neurosci 2022; 42:3879-3895. [PMID: 35387872 PMCID: PMC9097769 DOI: 10.1523/jneurosci.1463-21.2022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 12/20/2021] [Accepted: 01/27/2022] [Indexed: 01/18/2023] Open
Abstract
Calcium is an important second messenger regulating a bioenergetic response to the workloads triggered by neuronal activation. In embryonic mouse cortical neurons using glucose as only fuel, activation by NMDA elicits a strong workload (ATP demand)-dependent on Na+ and Ca2+ entry, and stimulates glucose uptake, glycolysis, pyruvate and lactate production, and oxidative phosphorylation (OXPHOS) in a Ca2+-dependent way. We find that Ca2+ upregulation of glycolysis, pyruvate levels, and respiration, but not glucose uptake, all depend on Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier, component of the malate-aspartate shuttle (MAS). MAS activation increases glycolysis, pyruvate production, and respiration, a process inhibited in the presence of BAPTA-AM, suggesting that the Ca2+ binding motifs in Aralar may be involved in the activation. Mitochondrial calcium uniporter (MCU) silencing had no effect, indicating that none of these processes required MCU-dependent mitochondrial Ca2+ uptake. The neuronal respiratory response to carbachol was also dependent on Aralar, but not on MCU. We find that mouse cortical neurons are endowed with a constitutive ER-to-mitochondria Ca2+ flow maintaining basal cell bioenergetics in which ryanodine receptors, RyR2, rather than InsP3R, are responsible for Ca2+ release, and in which MCU does not participate. The results reveal that, in neurons using glucose, MCU does not participate in OXPHOS regulation under basal or stimulated conditions, while Aralar-MAS appears as the major Ca2+-dependent pathway tuning simultaneously glycolysis and OXPHOS to neuronal activation.SIGNIFICANCE STATEMENT Neuronal activation increases cell workload to restore ion gradients altered by activation. Ca2+ is involved in matching increased workload with ATP production, but the mechanisms are still unknown. We find that glycolysis, pyruvate production, and neuronal respiration are stimulated on neuronal activation in a Ca2+-dependent way, independently of effects of Ca2+ as workload inducer. Mitochondrial calcium uniporter (MCU) does not play a relevant role in Ca2+ stimulated pyruvate production and oxygen consumption as both are unchanged in MCU silenced neurons. However, Ca2+ stimulation is blunt in the absence of Aralar, a Ca2+-binding mitochondrial carrier component of Malate-Aspartate Shuttle (MAS). The results suggest that Ca2+-regulated Aralar-MAS activation upregulates glycolysis and pyruvate production, which fuels mitochondrial respiration, through regulation of cytosolic NAD+/NADH ratio.
Collapse
Affiliation(s)
- Irene Pérez-Liébana
- Departamento de Biología Molecular, Instituto Universitario de Biología Molecular -IUBM, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain; and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, 28049, Spain
| | - Inés Juaristi
- Departamento de Biología Molecular, Instituto Universitario de Biología Molecular -IUBM, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain; and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, 28049, Spain
| | - Paloma González-Sánchez
- Departamento de Biología Molecular, Instituto Universitario de Biología Molecular -IUBM, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain; and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, 28049, Spain
| | - Luis González-Moreno
- Departamento de Biología Molecular, Instituto Universitario de Biología Molecular -IUBM, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain; and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, 28049, Spain
| | - Eduardo Rial
- Department of Structural and Chemical Biology, Centro de Investigaciones Biológicas Margarita Salas, Madrid, 28040, Spain
| | - Maša Podunavac
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106
| | - Armen Zakarian
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106
| | - Jordi Molgó
- Université Paris-Saclay, CEA, Institut des Sciences du Vivant Frédéric Joliot, ERL Centre National de la Recherche Scientifique no. 9004, Département Médicaments et Technologies pour la Santé, Service d'Ingénierie Moléculaire pour la Santé, Gif sur Yvette, F-91191, France
| | - Ainara Vallejo-Illarramendi
- IIS Biodonostia-University of the Basque Country, Donostia, Spain; CIBERNED (institute Carlos III), Madrid, Spain; and Department of Neurology, Hospital Universitario Donostia-OSAKIDETZA, San Sebastián, 20014, Spain
| | - Laura Mosqueira-Martín
- IIS Biodonostia-University of the Basque Country, Donostia, Spain; CIBERNED (institute Carlos III), Madrid, Spain; and Department of Neurology, Hospital Universitario Donostia-OSAKIDETZA, San Sebastián, 20014, Spain
| | - Adolfo Lopez de Munain
- IIS Biodonostia-University of the Basque Country, Donostia, Spain; CIBERNED (institute Carlos III), Madrid, Spain; and Department of Neurology, Hospital Universitario Donostia-OSAKIDETZA, San Sebastián, 20014, Spain
| | - Beatriz Pardo
- Departamento de Biología Molecular, Instituto Universitario de Biología Molecular -IUBM, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain; and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, 28049, Spain
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Instituto Universitario de Biología Molecular -IUBM, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain; and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, 28049, Spain
| | - Araceli Del Arco
- Departamento de Biología Molecular, Instituto Universitario de Biología Molecular -IUBM, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain; and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, 28049, Spain
- Facultad de Ciencias Ambientales y Bioquímica, Universidad de Castilla la Mancha, Toledo, 45071 Spain; and Centro Regional de Investigaciones Biomédicas, Unidad Asociada de Biomedicina, Toledo, 45071, Spain
| |
Collapse
|
4
|
Pardo B, Herrada-Soler E, Satrústegui J, Contreras L, del Arco A. AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease. Int J Mol Sci 2022; 23:528. [PMID: 35008954 PMCID: PMC8745132 DOI: 10.3390/ijms23010528] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 12/23/2021] [Accepted: 12/24/2021] [Indexed: 02/01/2023] Open
Abstract
AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria. The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA). Current evidence suggest that neurons are the main brain cell type expressing Aralar. However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency. Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects. The possible mechanism triggering the pathophysiological findings in AGC1 deficiency, such as epilepsy and postnatal hypomyelination observed in humans and mice, are also included. Many of these mechanisms arise from findings in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system. Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency. However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells. Further research is needed to clarify this question and delineate the transcellular metabolic fluxes that control brain functions. Finally, we discuss therapeutic approaches successfully used in AGC1-deficient patients and mice.
Collapse
Affiliation(s)
- Beatriz Pardo
- Departamento de Biología Molecular, Universidad Autónoma de Madrid, 28049 Madrid, Spain; (E.H.-S.); (J.S.); (L.C.)
- Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain;
- Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD), Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Eduardo Herrada-Soler
- Departamento de Biología Molecular, Universidad Autónoma de Madrid, 28049 Madrid, Spain; (E.H.-S.); (J.S.); (L.C.)
- Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain;
- Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD), Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Universidad Autónoma de Madrid, 28049 Madrid, Spain; (E.H.-S.); (J.S.); (L.C.)
- Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain;
- Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD), Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Laura Contreras
- Departamento de Biología Molecular, Universidad Autónoma de Madrid, 28049 Madrid, Spain; (E.H.-S.); (J.S.); (L.C.)
- Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain;
- Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD), Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Araceli del Arco
- Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain;
- Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD), Universidad Autónoma de Madrid, 28049 Madrid, Spain
- Centro Regional de Investigaciones Biomédicas, Facultad de Ciencias Ambientales y Bioquímica, Universidad de Castilla La Mancha, 45071 Toledo, Spain
| |
Collapse
|
5
|
Nuevo-Tapioles C, Santacatterina F, Sánchez-Garrido B, Arenas CN, Robledo-Bérgamo A, Martínez-Valero P, Cantarero L, Pardo B, Hoenicka J, Murphy MP, Satrústegui J, Palau F, Cuezva JM. Effective therapeutic strategies in a pre-clinical mouse model of Charcot-Marie-tooth disease. Hum Mol Genet 2021; 30:2441-2455. [PMID: 34274972 PMCID: PMC8643506 DOI: 10.1093/hmg/ddab207] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 07/14/2021] [Accepted: 07/14/2021] [Indexed: 12/13/2022] Open
Abstract
Charcot–Marie–Tooth (CMT) disease is a neuropathy that lacks effective therapy. CMT patients show degeneration of peripheral nerves, leading to muscle weakness and loss of proprioception. Loss of mitochondrial oxidative phosphorylation proteins and enzymes of the antioxidant response accompany degeneration of nerves in skin biopsies of CMT patients. Herein, we followed a drug-repurposing approach to find drugs in a Food and Drug Administration-approved library that could prevent development of CMT disease in the Gdap1-null mouse model. We found that the antibiotic florfenicol is a mitochondrial uncoupler that prevents the production of reactive oxygen species and activates respiration in human GDAP1-knockdown neuroblastoma cells and in dorsal root ganglion neurons of Gdap1-null mice. Treatment of CMT-affected Gdap1-null mice with florfenicol has no beneficial effect in the course of the disease. However, administration of florfenicol, or the antioxidant MitoQ, to pre-symptomatic GDAP1-null mice prevented weight gain and ameliorated the motor coordination deficiencies that developed in the Gdap1-null mice. Interestingly, both florfenicol and MitoQ halted the decay in mitochondrial and redox proteins in sciatic nerves of Gdap1-null mice, supporting that oxidative damage is implicated in the etiology of the neuropathy. These findings support the development of clinical trials for translation of these drugs for treatment of CMT patients.
Collapse
Affiliation(s)
- Cristina Nuevo-Tapioles
- Departamento de Biología Molecular.,Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), 28049, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII.,Instituto de Investigación Hospital 12 de Octubre; 28041, Madrid
| | - Fulvio Santacatterina
- Departamento de Biología Molecular.,Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), 28049, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII.,Instituto de Investigación Hospital 12 de Octubre; 28041, Madrid
| | - Brenda Sánchez-Garrido
- Departamento de Biología Molecular.,Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), 28049, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII.,Instituto de Investigación Hospital 12 de Octubre; 28041, Madrid
| | - Cristina Núñez Arenas
- Departamento de Biología Molecular.,Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), 28049, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII.,Instituto de Investigación Hospital 12 de Octubre; 28041, Madrid
| | | | - Paula Martínez-Valero
- Departamento de Biología Molecular.,Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), 28049, Madrid, Spain
| | - Lara Cantarero
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII.,Laboratorio de Neurogenética y Medicina Molecular- IPER, Institut de Recerca Sant Joan de Déu, Barcelona
| | - Beatriz Pardo
- Departamento de Biología Molecular.,Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), 28049, Madrid, Spain
| | - Janet Hoenicka
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII.,Laboratorio de Neurogenética y Medicina Molecular- IPER, Institut de Recerca Sant Joan de Déu, Barcelona
| | - Michael P Murphy
- Medical Research Council Mitochondrial Biology Unit, Wellcome Trust/MRC Building, University of Cambridge CB2 0XY, UK
| | - Jorgina Satrústegui
- Departamento de Biología Molecular.,Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), 28049, Madrid, Spain
| | - Francesc Palau
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII.,Laboratorio de Neurogenética y Medicina Molecular- IPER, Institut de Recerca Sant Joan de Déu, Barcelona.,Departament of Genetic and Molecular Medicine - IPER, Hospital Sant Joan de Déu.,Clinic Institute of Medicine and Dermatology (ICMiD), Hospital Clínic, Barcelona.,Division of Pediatrics, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
| | - José M Cuezva
- Departamento de Biología Molecular.,Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), 28049, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII.,Instituto de Investigación Hospital 12 de Octubre; 28041, Madrid
| |
Collapse
|
6
|
Puertas-Frías G, Del Arco A, Pardo B, Satrústegui J, Contreras L. Mitochondrial movement in Aralar/Slc25a12/AGC1 deficient cortical neurons. Neurochem Int 2019; 131:104541. [PMID: 31472174 DOI: 10.1016/j.neuint.2019.104541] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 07/25/2019] [Accepted: 08/28/2019] [Indexed: 12/12/2022]
Abstract
The elevated energy demands in the brain are fulfilled mainly by glucose catabolism. In highly polarized neurons, about 10-50% of mitochondria are transported along microtubules using mitochondrial-born ATP to locations with high energy requirements. In this report, we have investigated the impact of Aralar deficiency on mitochondrial transport in cultured cortical neurons. Aralar/slc25a12/AGC1 is the neuronal isoform of the aspartate-glutamate mitochondrial carrier, a component of the malate-aspartate shuttle (MAS) which plays an important role in redox balance, which is essential to maintain glycolytic pyruvate supply to neuronal mitochondria. Using live imaging microscopy we observed that the lack of Aralar does not affect the number of moving mitochondria nor the Ca2+-induced stop, the only difference being a 10% increase in mitochondrial velocity in Aralar deficient neurons. Therefore, we evaluated the possible fuels used in each case by studying the relative contribution of oxidative phosphorylation and glycolysis to mitochondrial movement using specific inhibitors. We found that the ATP synthase inhibitor oligomycin caused a smaller inhibition of mitochondrial movement in Aralar-KO than control neurons, whereas the glycolysis inhibitor iodoacetate had similar effects in neurons from both genotypes. In line with these findings, the decrease in cytosolic ATP/ADP ratio caused by oligomycin was more pronounced in control than in Aralar-KO neurons, but no differences were observed with iodoacetate. Oligomycin effect was reverted by aralar re-expression in knock out cultures. As mitochondrial movement is not reduced in Aralar-KO neurons, these results suggest that these neurons may use an additional pathway for mitochondria movement and ATP/ADP ratio maintenance.
Collapse
Affiliation(s)
- Guillermo Puertas-Frías
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, 28049, Madrid, Spain
| | - Araceli Del Arco
- Facultad de Ciencias Ambientales y Bioquímica, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla La Mancha, 45071, Toledo, Spain; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IISFJD), 28049, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28049, Madrid, Spain
| | - Beatriz Pardo
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, 28049, Madrid, Spain; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IISFJD), 28049, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28049, Madrid, Spain
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, 28049, Madrid, Spain; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IISFJD), 28049, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28049, Madrid, Spain
| | - Laura Contreras
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, 28049, Madrid, Spain; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IISFJD), 28049, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28049, Madrid, Spain.
| |
Collapse
|
7
|
Juaristi I, Contreras L, González-Sánchez P, Pérez-Liébana I, González-Moreno L, Pardo B, Del Arco A, Satrústegui J. The Response to Stimulation in Neurons and Astrocytes. Neurochem Res 2019; 44:2385-2391. [PMID: 31016552 DOI: 10.1007/s11064-019-02803-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Revised: 04/10/2019] [Accepted: 04/11/2019] [Indexed: 12/19/2022]
Abstract
The brain uses mainly glucose as fuel with an index of glucose to oxygen utilization close to 6, the maximal index if all glucose was completely oxidized. However, this high oxidative index, contrasts with the metabolic traits of the major cell types in the brain studied in culture, neurons and astrocytes, including the selective use of the malate-aspartate shuttle (MAS) in neurons and the glycerol-phosphate shuttle in astrocytes. Metabolic interactions among these cell types may partly explain the high oxidative index of the brain. In vivo, neuronal activation results in a decrease in the oxygen glucose index, which has been attributed to a stimulation of glycolysis and lactate production in astrocytes in response to glutamate uptake (astrocyte-neuron lactate shuttle, ANLS). Recent findings indicate that this is accompanied with a stimulation of pyruvate formation and astrocyte respiration, indicating that lactate formation is not the only astrocytic response to neuronal activation. ANLS proposes that neurons utilize lactate produced by neighboring astrocytes. Indeed, neurons can use lactate to support an increase in respiration with different workloads, and this depends on the Ca2+ activation of MAS. However, whether this activation operates in the brain, particularly at high stimulation conditions, remains to be established.
Collapse
Affiliation(s)
- Inés Juaristi
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Nicolás Cabrera, 1, 28049, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Laura Contreras
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Nicolás Cabrera, 1, 28049, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Paloma González-Sánchez
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Nicolás Cabrera, 1, 28049, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Irene Pérez-Liébana
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Nicolás Cabrera, 1, 28049, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Luis González-Moreno
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Nicolás Cabrera, 1, 28049, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Beatriz Pardo
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Nicolás Cabrera, 1, 28049, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Araceli Del Arco
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
- Facultad de Ciencias Ambientales y Bioquímica, Universidad de Castilla la Mancha, Toledo, Spain
- Centro Regional de Investigaciones Biomédicas, Unidad Asociada de Biomedicina UCLM-CSIC, Toledo, Spain
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Nicolás Cabrera, 1, 28049, Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
| |
Collapse
|
8
|
Juaristi I, Llorente-Folch I, Satrústegui J, Del Arco A. Extracellular ATP and glutamate drive pyruvate production and energy demand to regulate mitochondrial respiration in astrocytes. Glia 2019; 67:759-774. [PMID: 30623988 DOI: 10.1002/glia.23574] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 11/08/2018] [Accepted: 11/13/2018] [Indexed: 12/26/2022]
Abstract
Astrocytes respond to energetic demands by upregulating glycolysis, lactate production, and respiration. This study addresses the role of respiration and calcium regulation of respiration as part of the astrocyte response to the workloads caused by extracellular ATP and glutamate. Extracellular ATP (100 μM to 1 mM) causes a Ca2+ -dependent workload and fall of the cytosolic ATP/ADP ratio which acutely increases astrocytes respiration. Part of this increase is related to a Ca2+ -dependent upregulation of cytosolic pyruvate production. Conversely, glutamate (200 μM) causes a Na+ , but not Ca2+ , dependent workload even though glutamate-induced Ca2+ signals readily reach mitochondria. The glutamate workload triggers a rapid fall in the cytosolic ATP/ADP ratio and stimulation of respiration. These effects are mimicked by D-aspartate a nonmetabolized agonist of the glutamate transporter, but not by a metabotropic glutamate receptor agonist, indicating a major role of Na+ -dependent workload in stimulated respiration. Glutamate-induced increase in respiration is linked to a rapid increase in glycolytic pyruvate production, suggesting that both glutamate and extracellular ATP cause an increase in astrocyte respiration fueled by workload-induced increase in pyruvate production. However, glutamate-induced pyruvate production is partly resistant to glycolysis blockers (iodoacetate), indicating that oxidative consumption of glutamate also contributes to stimulated respiration. As stimulation of respiration by ATP and glutamate are similar and pyruvate production smaller in the first case, the results suggest that the response to extracellular ATP is a Ca2+ -dependent upregulation of respiration added to glycolysis upregulation. The global contribution of astrocyte respiratory responses to brain oxygen consumption is an open question.
Collapse
Affiliation(s)
- Inés Juaristi
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Irene Llorente-Folch
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.,Center for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Araceli Del Arco
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.,Facultad de Ciencias Ambientales y Bioquímica, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla la Mancha, Toledo, Spain
| |
Collapse
|
9
|
González-Sánchez P, Del Arco A, Esteban JA, Satrústegui J. Store-Operated Calcium Entry Is Required for mGluR-Dependent Long Term Depression in Cortical Neurons. Front Cell Neurosci 2017; 11:363. [PMID: 29311823 PMCID: PMC5735122 DOI: 10.3389/fncel.2017.00363] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Accepted: 11/03/2017] [Indexed: 01/13/2023] Open
Abstract
Store-operated calcium entry (SOCE) is a Calcium (Ca2+) influx pathway activated by depletion of intracellular stores that occurs in eukaryotic cells. In neurons, the presence and functions of SOCE are still in question. Here, we show evidences for the existence of SOCE in primary mouse cortical neurons. Endoplasmic reticulum (ER)-Ca2+ depletion using thapsigargin (Tg) triggered a maintained cytosolic Ca2+ increase, which rapidly returned to basal level in the presence of the SOCE blockers 2-Aminoethoxydiphenyl borate (2-APB) and YM-58483. Neural SOCE is also engaged by activation of metabotropic glutamate receptors (mGluRs) with (S)-3,5-dihydroxyphenylglycine (DHPG) (agonist of group I mGluRs), being an essential mechanism to maintain the mGluR-driven Ca2+ signal. Activation of group I of mGluRs triggers long-term depression (LTD) in many brain regions, but the underlying mechanism and, specifically, the necessity of Ca2+ increase in the postsynaptic neuron is controversial. In primary cortical neurons, we now show that the inhibition of Ca2+ influx through SOCE impaired DHPG-LTD, pointing out a key function of calcium and SOCE in synaptic plasticity.
Collapse
Affiliation(s)
- Paloma González-Sánchez
- Department of Molecular Biology, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Araceli Del Arco
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.,Facultad de Ciencias Ambientales y Bioquímica, Universidad de Castilla la Mancha, Toledo, Spain
| | - José A Esteban
- Department of Molecular Neurobiology, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain
| | - Jorgina Satrústegui
- Department of Molecular Biology, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| |
Collapse
|
10
|
Gómez-Nieto B, Gismera MJ, Sevilla MT, Satrústegui J, Procopio JR. Micro-sampling method based on high-resolution continuum source graphite furnace atomic absorption spectrometry for calcium determination in blood and mitochondrial suspensions. Talanta 2017; 170:15-21. [PMID: 28501151 DOI: 10.1016/j.talanta.2017.03.086] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Revised: 03/23/2017] [Accepted: 03/28/2017] [Indexed: 12/31/2022]
Abstract
A micro-sampling and straightforward method based on high resolution continuum source atomic absorption spectrometry (HR-CS AAS) was developed to determine extracellular and intracellular Ca in samples of interest in clinical and biomedical analysis. Solid sampling platforms were used to introduce the micro-samples into the graphite furnace atomizer. The secondary absorption line for Ca, located at 239.856nm, was selected to carry out the measurements. Experimental parameters such as pyrolysis and atomization temperatures and the amount of sample introduced for the measurements were optimized. Calibration was performed using aqueous standards and the approach to measure at the wings of the absorption lines was employed for the expansion of the linear response range. The limit of detection was of 0.02mgL-1 Ca (0.39ng Ca) and the upper limit of linear range was increased up to 8.0mgL-1 Ca (160ng Ca). The proposed method was used to determine Ca in mitochondrial suspensions and whole blood samples with successful results. Adequate recoveries (within 91-107%) were obtained in the tests performed for validation purposes.
Collapse
Affiliation(s)
- Beatriz Gómez-Nieto
- Departamento de Química Analítica y Análisis Instrumental, Facultad de Ciencias, Avda. Francisco Tomás y Valiente, 7, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Mª Jesús Gismera
- Departamento de Química Analítica y Análisis Instrumental, Facultad de Ciencias, Avda. Francisco Tomás y Valiente, 7, Universidad Autónoma de Madrid, 28049 Madrid, Spain.
| | - Mª Teresa Sevilla
- Departamento de Química Analítica y Análisis Instrumental, Facultad de Ciencias, Avda. Francisco Tomás y Valiente, 7, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Jesús R Procopio
- Departamento de Química Analítica y Análisis Instrumental, Facultad de Ciencias, Avda. Francisco Tomás y Valiente, 7, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| |
Collapse
|
11
|
Remacha L, Comino-Méndez I, Richter S, Contreras L, Currás-Freixes M, Pita G, Letón R, Galarreta A, Torres-Pérez R, Honrado E, Jiménez S, Maestre L, Moran S, Esteller M, Satrústegui J, Eisenhofer G, Robledo M, Cascón A. Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clin Cancer Res 2017; 23:6315-6324. [PMID: 28720665 DOI: 10.1158/1078-0432.ccr-16-2250] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Revised: 05/22/2017] [Accepted: 07/12/2017] [Indexed: 11/16/2022]
Abstract
Purpose: Mutations in Krebs cycle genes are frequently found in patients with pheochromocytomas/paragangliomas. Disruption of SDH, FH or MDH2 enzymatic activities lead to accumulation of specific metabolites, which give rise to epigenetic changes in the genome that cause a characteristic hypermethylated phenotype. Tumors showing this phenotype, but no alterations in the known predisposing genes, could harbor mutations in other Krebs cycle genes.Experimental Design: We used downregulation and methylation of RBP1, as a marker of a hypermethylation phenotype, to select eleven pheochromocytomas and paragangliomas for targeted exome sequencing of a panel of Krebs cycle-related genes. Methylation profiling, metabolite assessment and additional analyses were also performed in selected cases.Results: One of the 11 tumors was found to carry a known cancer-predisposing somatic mutation in IDH1 A variant in GOT2, c.357A>T, found in a patient with multiple tumors, was associated with higher tumor mRNA and protein expression levels, increased GOT2 enzymatic activity in lymphoblastic cells, and altered metabolite ratios both in tumors and in GOT2 knockdown HeLa cells transfected with the variant. Array methylation-based analysis uncovered a somatic epigenetic mutation in SDHC in a patient with multiple pheochromocytomas and a gastrointestinal stromal tumor. Finally, a truncating germline IDH3B mutation was found in a patient with a single paraganglioma showing an altered α-ketoglutarate/isocitrate ratio.Conclusions: This study further attests to the relevance of the Krebs cycle in the development of PCC and PGL, and points to a potential role of other metabolic enzymes involved in metabolite exchange between mitochondria and cytosol. Clin Cancer Res; 23(20); 6315-24. ©2017 AACR.
Collapse
Affiliation(s)
- Laura Remacha
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Iñaki Comino-Méndez
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Susan Richter
- Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Laura Contreras
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - María Currás-Freixes
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Guillermo Pita
- Human Genotyping Unit-CeGen, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Rocío Letón
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Antonio Galarreta
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Rafael Torres-Pérez
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Scherezade Jiménez
- Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Lorena Maestre
- Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Sebastian Moran
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - Manel Esteller
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
| | - Jorgina Satrústegui
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Graeme Eisenhofer
- Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Mercedes Robledo
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Alberto Cascón
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. .,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| |
Collapse
|
12
|
Juaristi I, García-Martín ML, Rodrigues TB, Satrústegui J, Llorente-Folch I, Pardo B. ARALAR/AGC1 deficiency, a neurodevelopmental disorder with severe impairment of neuronal mitochondrial respiration, does not produce a primary increase in brain lactate. J Neurochem 2017; 142:132-139. [PMID: 28429368 DOI: 10.1111/jnc.14047] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Revised: 03/07/2017] [Accepted: 04/07/2017] [Indexed: 12/28/2022]
Abstract
ARALAR/AGC1 (aspartate-glutamate mitochondrial carrier 1) is an important component of the NADH malate-aspartate shuttle (MAS). AGC1-deficiency is a rare disease causing global cerebral hypomyelination, developmental arrest, hypotonia, and epilepsy (OMIM ID #612949); the aralar-KO mouse recapitulates the major findings in humans. This study was aimed at understanding the impact of ARALAR-deficiency in brain lactate levels as a biomarker. We report that lactate was equally abundant in wild-type and aralar-KO mouse brain in vivo at postnatal day 17. We find that lactate production upon mitochondrial blockade depends on up-regulation of lactate formation in astrocytes rather than in neurons. However, ARALAR-deficiency decreased cell respiration in neurons, not astrocytes, which maintained unchanged respiration and lactate production. As the primary site of ARALAR-deficiency is neuronal, this explains the lack of accumulation of brain lactate in ARALAR-deficiency in humans and mice. On the other hand, we find that the cytosolic and mitochondrial components of the glycerol phosphate shuttle are present in astrocytes with similar activities. This suggests that glycerol phosphate shuttle is the main NADH shuttle in astrocytes and explains the absence of effects of ARALAR-deficiency in these cells.
Collapse
Affiliation(s)
- Inés Juaristi
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, Madrid, Spain.,CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid, Madrid, Spain.,Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD); Universidad Autónoma de Madrid, Madrid, Spain
| | - María L García-Martín
- Laboratory of Metabolomics and Molecular Imaging, BIONAND, Andalusian Centre for Nanomedicine and Biotechnology (Junta de Andalucía, Universidad de Málaga), Malaga, Spain
| | - Tiago B Rodrigues
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.,Department of Biochemistry, University of Cambridge, Cambridge, UK
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, Madrid, Spain.,CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid, Madrid, Spain.,Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD); Universidad Autónoma de Madrid, Madrid, Spain
| | - Irene Llorente-Folch
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, Madrid, Spain.,CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid, Madrid, Spain.,Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD); Universidad Autónoma de Madrid, Madrid, Spain
| | - Beatriz Pardo
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, Madrid, Spain.,CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid, Madrid, Spain.,Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD); Universidad Autónoma de Madrid, Madrid, Spain
| |
Collapse
|
13
|
Pérez-Cañamás A, Benvegnù S, Rueda CB, Rábano A, Satrústegui J, Ledesma MD. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. Mol Psychiatry 2017; 22:711-723. [PMID: 27620840 DOI: 10.1038/mp.2016.148] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Revised: 06/28/2016] [Accepted: 07/13/2016] [Indexed: 01/06/2023]
Abstract
Niemann-Pick disease type A (NPA) is a rare lysosomal storage disorder characterized by severe neurological alterations that leads to death in childhood. Loss-of-function mutations in the acid sphingomyelinase (ASM) gene cause NPA, and result in the accumulation of sphingomyelin (SM) in lysosomes and plasma membrane of neurons. Using ASM knockout (ASMko) mice as a NPA disease model, we investigated how high SM levels contribute to neural pathology in NPA. We found high levels of oxidative stress both in neurons from these mice and a NPA patient. Impaired activity of the plasma membrane calcium ATPase (PMCA) increases intracellular calcium. SM induces PMCA decreased activity, which causes oxidative stress. Incubating ASMko-cultured neurons in the histone deacetylase inhibitor, SAHA, restores PMCA activity and calcium homeostasis and, consequently, reduces the increased levels of oxidative stress. No recovery occurs when PMCA activity is pharmacologically impaired or genetically inhibited in vitro. Oral administration of SAHA prevents oxidative stress and neurodegeneration, and improves behavioral performance in ASMko mice. These results demonstrate a critical role for plasma membrane SM in neuronal calcium regulation. Thus, we identify changes in PMCA-triggered calcium homeostasis as an upstream mediator for NPA pathology. These findings can stimulate new approaches for pharmacological remediation in a disease with no current clinical treatments.
Collapse
Affiliation(s)
- A Pérez-Cañamás
- Centro Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
| | - S Benvegnù
- Centro Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
| | - C B Rueda
- Centro Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Instituto de Investigaciones Sanitarias, Fundación Jiménez Díaz, Madrid, Spain
| | - A Rábano
- Fundación Centro de Investigación de Enfermedades Neurológicas (CIEN), Madrid, Spain
| | - J Satrústegui
- Centro Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Instituto de Investigaciones Sanitarias, Fundación Jiménez Díaz, Madrid, Spain
| | - M D Ledesma
- Centro Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
| |
Collapse
|
14
|
González-Sánchez P, Pla-Martín D, Martínez-Valero P, Rueda CB, Calpena E, Del Arco A, Palau F, Satrústegui J. CMT-linked loss-of-function mutations in GDAP1 impair store-operated Ca 2+ entry-stimulated respiration. Sci Rep 2017; 7:42993. [PMID: 28220846 PMCID: PMC5318958 DOI: 10.1038/srep42993] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 01/18/2017] [Indexed: 12/18/2022] Open
Abstract
GDAP1 is an outer mitochondrial membrane protein involved in Charcot-Marie-Tooth (CMT) disease. Lack of GDAP1 gives rise to altered mitochondrial networks and endoplasmic reticulum (ER)-mitochondrial interactions resulting in a decreased ER-Ca2+ levels along with a defect on store-operated calcium entry (SOCE) related to a misallocation of mitochondria to subplasmalemmal sites. The defect on SOCE is mimicked by MCU silencing or mitochondrial depolarization, which prevent mitochondrial calcium uptake. Ca2+ release from de ER and Ca2+ inflow through SOCE in neuroblastoma cells result in a Ca2+-dependent upregulation of respiration which is blunted in GDAP1 silenced cells. Reduced SOCE in cells with CMT recessive missense mutations in the α-loop of GDAP1, but not dominant mutations, was associated with smaller SOCE-stimulated respiration. These cases of GDAP1 deficiency also resulted in a decreased ER-Ca2+ levels which may have pathological implications. The results suggest that CMT neurons may be under energetic constraints upon stimulation by Ca2+ mobilization agonists and point to a potential role of perturbed mitochondria-ER interaction related to energy metabolism in forms of CMT caused by some of the recessive or null mutations of GDAP1.
Collapse
Affiliation(s)
- Paloma González-Sánchez
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, 28049, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz, IIS-FJD, Madrid, 28040, Spain
| | - David Pla-Martín
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.,Program in Rare and Genetic Diseases and IBV/CSIC Associated Unit, Centro de Investigación Príncipe Felipe, Valencia, 46012, Spain
| | - Paula Martínez-Valero
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, 28049, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz, IIS-FJD, Madrid, 28040, Spain
| | - Carlos B Rueda
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, 28049, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz, IIS-FJD, Madrid, 28040, Spain
| | - Eduardo Calpena
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.,Program in Rare and Genetic Diseases and IBV/CSIC Associated Unit, Centro de Investigación Príncipe Felipe, Valencia, 46012, Spain
| | - Araceli Del Arco
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz, IIS-FJD, Madrid, 28040, Spain.,Facultad de Ciencias Ambientales y Bioquímica, Universidad de Castilla la Mancha, Toledo, 45071, Spain
| | - Francesc Palau
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.,Program in Rare and Genetic Diseases and IBV/CSIC Associated Unit, Centro de Investigación Príncipe Felipe, Valencia, 46012, Spain.,Institut de Recerca Sant Joan de Déu and Hospital Sant Joan de Déu, Barcelona 08950, Spain.,Pediatrics Division, University of Barcelona School of Medicine, Barcelona, Spain
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, 28049, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.,Instituto de Investigación Sanitaria Fundación Jiménez Díaz, IIS-FJD, Madrid, 28040, Spain
| |
Collapse
|
15
|
Contreras L, Ramirez L, Du J, Hurley JB, Satrústegui J, de la Villa P. Deficient glucose and glutamine metabolism in Aralar/AGC1/Slc25a12 knockout mice contributes to altered visual function. Mol Vis 2016; 22:1198-1212. [PMID: 27746674 PMCID: PMC5063090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Accepted: 10/10/2016] [Indexed: 11/10/2022] Open
Abstract
PURPOSE To characterize the vision phenotype of mice lacking Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier mutated in global cerebral hypomyelination (OMIM 612949). METHODS We tested overnight dark-adapted control and aralar-deficient mice for the standard full electroretinogram (ERG) response. The metabolic stress of dark-adaptation was reduced by 5 min illumination after which the ERG response was monitored in darkness. We used the electrical response to two identical saturating light flashes (paired-flash stimulation) to isolate the inner retina and photoreceptor responses. Retinal morphology was examined with hematoxylin and eosin staining, immunohistochemistry of antibodies against retinal cells, and 4',6-diamidino-2-phenylindole (DAPI) labeling. RESULTS Aralar plays a pivotal role in retina metabolism as aralar provides de novo synthesis pathway for glutamine, protects glutamate from oxidation, and is required for efficient glucose oxidative metabolism. Aralar-deficient mice are not blind as their retinas have light-evoked activity. However, we report an approximate 50% decrease in the ERG amplitude response in the light-evoked activity of dark-adapted retinas from aralar-deficient mice, in spite of normal retina histology. The defective response is partly reversed by exposure to a brief illumination period, which lowers the metabolic stress of dark-adaptation. The metabolic stress and ERG alteration takes place primarily in photoreceptors, but the response to two flashes applied in fast succession also revealed an alteration in synaptic transmission consistent with an imbalance of glutamate and an energy deficit in the inner retina neurons. CONCLUSIONS We propose that compromised glucose oxidation and altered glutamine and glutamate metabolism in the absence of aralar are responsible for the phenotype reported.
Collapse
Affiliation(s)
- Laura Contreras
- Centro de Biología Molecular Severo Ochoa CSIC-UAM, CI.B.E.R. de Enfermedades Raras, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - Laura Ramirez
- Department of Systems Biology, University of Alcalá, Alcalá de Henares, Spain
| | - Jianhai Du
- Department of Biochemistry, University of Washington, Seattle, WA.,Department of Ophthalmology, University of Washington, Seattle, WA
| | - James B. Hurley
- Department of Biochemistry, University of Washington, Seattle, WA.,Department of Ophthalmology, University of Washington, Seattle, WA
| | - Jorgina Satrústegui
- Centro de Biología Molecular Severo Ochoa CSIC-UAM, CI.B.E.R. de Enfermedades Raras, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - Pedro de la Villa
- Department of Systems Biology, University of Alcalá, Alcalá de Henares, Spain
| |
Collapse
|
16
|
Santacatterina F, Sánchez-Cenizo L, Formentini L, Mobasher MA, Casas E, Rueda CB, Martínez-Reyes I, de Arenas CN, García-Bermúdez J, Zapata JM, Sánchez-Aragó M, Satrústegui J, Valverde ÁM, Cuezva JM. Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumor-promoter metabolic state. Oncotarget 2016; 7:490-508. [PMID: 26595676 PMCID: PMC4808013 DOI: 10.18632/oncotarget.6357] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 11/14/2015] [Indexed: 02/07/2023] Open
Abstract
The ATPase Inhibitory Factor 1 (IF1) is an inhibitor of the mitochondrial H+-ATP synthase that regulates the activity of both oxidative phosphorylation (OXPHOS) and cell death. Here, we have developed transgenic Tet-On and Tet-Off mice that express a mutant active form of hIF1 in the hepatocytes to restrain OXPHOS in the liver to investigate the relevance of mitochondrial activity in hepatocarcinogenesis. The expression of hIF1 promotes the inhibition of OXPHOS in both Tet-On and Tet-Off mouse models and induces a state of metabolic preconditioning guided by the activation of the stress kinases AMPK and p38 MAPK. Expression of the transgene significantly augmented proliferation and apoptotic resistance of carcinoma cells, which contributed to an enhanced diethylnitrosamine-induced liver carcinogenesis. Moreover, the expression of hIF1 also diminished acetaminophen-induced apoptosis, which is unrelated to differences in permeability transition pore opening. Mechanistically, cell survival in hIF1-preconditioned hepatocytes results from a nuclear factor-erythroid 2-related factor (Nrf2)-guided antioxidant response. The results emphasize in vivo that a metabolic phenotype with a restrained OXPHOS in the liver is prone to the development of cancer.
Collapse
Affiliation(s)
- Fulvio Santacatterina
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Centro de Investigación Hospital 12 de Octubre, ISCIII, Madrid, Spain
| | - Laura Sánchez-Cenizo
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Centro de Investigación Hospital 12 de Octubre, ISCIII, Madrid, Spain
| | - Laura Formentini
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Centro de Investigación Hospital 12 de Octubre, ISCIII, Madrid, Spain
| | - Maysa A. Mobasher
- Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
| | - Estela Casas
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Centro de Investigación Hospital 12 de Octubre, ISCIII, Madrid, Spain
| | - Carlos B. Rueda
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Inmaculada Martínez-Reyes
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Centro de Investigación Hospital 12 de Octubre, ISCIII, Madrid, Spain
| | - Cristina Núñez de Arenas
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Javier García-Bermúdez
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Centro de Investigación Hospital 12 de Octubre, ISCIII, Madrid, Spain
| | - Juan M. Zapata
- Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM, Madrid, Spain
| | - María Sánchez-Aragó
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Centro de Investigación Hospital 12 de Octubre, ISCIII, Madrid, Spain
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Ángela M. Valverde
- Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
| | - José M. Cuezva
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Centro de Investigación Hospital 12 de Octubre, ISCIII, Madrid, Spain
| |
Collapse
|
17
|
Du J, Rountree A, Cleghorn WM, Contreras L, Lindsay KJ, Sadilek M, Gu H, Djukovic D, Raftery D, Satrústegui J, Kanow M, Chan L, Tsang SH, Sweet IR, Hurley JB. Phototransduction Influences Metabolic Flux and Nucleotide Metabolism in Mouse Retina. J Biol Chem 2015; 291:4698-710. [PMID: 26677218 DOI: 10.1074/jbc.m115.698985] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Indexed: 01/20/2023] Open
Abstract
Production of energy in a cell must keep pace with demand. Photoreceptors use ATP to maintain ion gradients in darkness, whereas in light they use it to support phototransduction. Matching production with consumption can be accomplished by coupling production directly to consumption. Alternatively, production can be set by a signal that anticipates demand. In this report we investigate the hypothesis that signaling through phototransduction controls production of energy in mouse retinas. We found that respiration in mouse retinas is not coupled tightly to ATP consumption. By analyzing metabolic flux in mouse retinas, we also found that phototransduction slows metabolic flux through glycolysis and through intermediates of the citric acid cycle. We also evaluated the relative contributions of regulation of the activities of α-ketoglutarate dehydrogenase and the aspartate-glutamate carrier 1. In addition, a comprehensive analysis of the retinal metabolome showed that phototransduction also influences steady-state concentrations of 5'-GMP, ribose-5-phosphate, ketone bodies, and purines.
Collapse
Affiliation(s)
- Jianhai Du
- From the Department of Biochemistry, Department of Ophthalmology, University of Washington, Seattle, Washington 98109
| | | | | | - Laura Contreras
- Department of Molecular Biology, Centre for Molecular Biology Severo Ochoa, Universidad Autonoma de Madrid-Consejo Superior de Investigaciones Científicas, CIBER of Rare Diseases (CIBERER), and Health Research Institute Jimenez Diaz Foundation, Autonomous University of Madrid, 28049 Madrid, Spain
| | | | | | - Haiwei Gu
- Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine
| | - Danijel Djukovic
- Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine
| | - Dan Raftery
- Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine
| | - Jorgina Satrústegui
- Department of Molecular Biology, Centre for Molecular Biology Severo Ochoa, Universidad Autonoma de Madrid-Consejo Superior de Investigaciones Científicas, CIBER of Rare Diseases (CIBERER), and Health Research Institute Jimenez Diaz Foundation, Autonomous University of Madrid, 28049 Madrid, Spain
| | | | - Lawrence Chan
- Bernard and Shirlee Brown Glaucoma Laboratory and Barbara and Donald Jonas Stem Cell Laboratory, Department of Ophthalmology, Columbia University, New York, New York, and
| | - Stephen H Tsang
- Bernard and Shirlee Brown Glaucoma Laboratory and Barbara and Donald Jonas Stem Cell Laboratory, Department of Ophthalmology, Columbia University, New York, New York, and Department of Pathology and Cell Biology and Institute of Human Nutrition, Columbia University, New York, New York 10032
| | | | - James B Hurley
- From the Department of Biochemistry, Department of Ophthalmology, University of Washington, Seattle, Washington 98109,
| |
Collapse
|
18
|
Cascón A, Comino-Méndez I, Currás-Freixes M, de Cubas AA, Contreras L, Richter S, Peitzsch M, Mancikova V, Inglada-Pérez L, Pérez-Barrios A, Calatayud M, Azriel S, Villar-Vicente R, Aller J, Setién F, Moran S, Garcia JF, Río-Machín A, Letón R, Gómez-Graña Á, Apellániz-Ruiz M, Roncador G, Esteller M, Rodríguez-Antona C, Satrústegui J, Eisenhofer G, Urioste M, Robledo M. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. J Natl Cancer Inst 2015; 107:djv053. [PMID: 25766404 DOI: 10.1093/jnci/djv053] [Citation(s) in RCA: 111] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Disruption of the Krebs cycle is a hallmark of cancer. IDH1 and IDH2 mutations are found in many neoplasms, and germline alterations in SDH genes and FH predispose to pheochromocytoma/paraganglioma and other cancers. We describe a paraganglioma family carrying a germline mutation in MDH2, which encodes a Krebs cycle enzyme. Whole-exome sequencing was applied to tumor DNA obtained from a man age 55 years diagnosed with multiple malignant paragangliomas. Data were analyzed with the two-sided Student's t and Mann-Whitney U tests with Bonferroni correction for multiple comparisons. Between six- and 14-fold lower levels of MDH2 expression were observed in MDH2-mutated tumors compared with control patients. Knockdown (KD) of MDH2 in HeLa cells by shRNA triggered the accumulation of both malate (mean ± SD: wild-type [WT] = 1±0.18; KD = 2.24±0.17, P = .043) and fumarate (WT = 1±0.06; KD = 2.6±0.25, P = .033), which was reversed by transient introduction of WT MDH2 cDNA. Segregation of the mutation with disease and absence of MDH2 in mutated tumors revealed MDH2 as a novel pheochromocytoma/paraganglioma susceptibility gene.
Collapse
Affiliation(s)
- Alberto Cascón
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Iñaki Comino-Méndez
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - María Currás-Freixes
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Aguirre A de Cubas
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Laura Contreras
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Susan Richter
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Mirko Peitzsch
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Veronika Mancikova
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Lucía Inglada-Pérez
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Andrés Pérez-Barrios
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - María Calatayud
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Sharona Azriel
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Rosa Villar-Vicente
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Javier Aller
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Fernando Setién
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Sebastian Moran
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Juan F Garcia
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Ana Río-Machín
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Rocío Letón
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Álvaro Gómez-Graña
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - María Apellániz-Ruiz
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Giovanna Roncador
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Manel Esteller
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Cristina Rodríguez-Antona
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Jorgina Satrústegui
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Graeme Eisenhofer
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Miguel Urioste
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain
| | - Mercedes Robledo
- : Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain (AC, ICM, MCF, AAdC, VM, LIP, RL, AGG, MAR, CRA, MR); Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (AC, LC, LIP, CRA, JS, MU, MR); Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain (LC, JS); Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (SR, MP, GE); Departments of Pathology (APB) and Endocrinology and Nutrition Service (MC), Hospital 12 de Octubre, Madrid, Spain; Endocrinology Service, Hospital Infanta Sofía, San Sebastián de los Reyes, Spain (SA); Department of Endocrinology and Nutrition Service, Hospital de Fuenlabrada, Madrid, Spain (RVV); Endocrinology Service, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain (JA); Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain (FS, SM, ME); Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain (JFG); Molecular Cytogenetics Group (ARM), Monoclonal Antibodies Unit, Biotechnology Programme (GR), and Familial Cancer Clinical Unit (MU), Spanish National Cancer Research Centre, Madrid, Spain.
| |
Collapse
|
19
|
Du J, Cleghorn WM, Contreras L, Lindsay K, Rountree AM, Chertov AO, Turner SJ, Sahaboglu A, Linton J, Sadilek M, Satrústegui J, Sweet IR, Paquet-Durand F, Hurley JB. Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. J Biol Chem 2013; 288:36129-40. [PMID: 24187136 DOI: 10.1074/jbc.m113.507285] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Transport of pyruvate into mitochondria by the mitochondrial pyruvate carrier is crucial for complete oxidation of glucose and for biosynthesis of amino acids and lipids. Zaprinast is a well known phosphodiesterase inhibitor and lead compound for sildenafil. We found Zaprinast alters the metabolomic profile of mitochondrial intermediates and amino acids in retina and brain. This metabolic effect of Zaprinast does not depend on inhibition of phosphodiesterase activity. By providing (13)C-labeled glucose and glutamine as fuels, we found that the metabolic profile of the Zaprinast effect is nearly identical to that of inhibitors of the mitochondrial pyruvate carrier. Both stimulate oxidation of glutamate and massive accumulation of aspartate. Moreover, Zaprinast inhibits pyruvate-driven O2 consumption in brain mitochondria and blocks mitochondrial pyruvate carrier in liver mitochondria. Inactivation of the aspartate glutamate carrier in retina does not attenuate the metabolic effect of Zaprinast. Our results show that Zaprinast is a potent inhibitor of mitochondrial pyruvate carrier activity, and this action causes aspartate to accumulate at the expense of glutamate. Our findings show that Zaprinast is a specific mitochondrial pyruvate carrier (MPC) inhibitor and may help to elucidate the roles of MPC in amino acid metabolism and hypoglycemia.
Collapse
|
20
|
Pardo B, Contreras L, Satrústegui J. De novo Synthesis of Glial Glutamate and Glutamine in Young Mice Requires Aspartate Provided by the Neuronal Mitochondrial Aspartate-Glutamate Carrier Aralar/AGC1. Front Endocrinol (Lausanne) 2013; 4:149. [PMID: 24133485 PMCID: PMC3796713 DOI: 10.3389/fendo.2013.00149] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Accepted: 10/02/2013] [Indexed: 01/14/2023] Open
Affiliation(s)
- Beatriz Pardo
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid, Madrid, Spain
- *Correspondence:
| | - Laura Contreras
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid, Madrid, Spain
| | - Jorgina Satrústegui
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid, Madrid, Spain
| |
Collapse
|
21
|
Pla-Martín D, Rueda CB, Estela A, Sánchez-Piris M, González-Sánchez P, Traba J, de la Fuente S, Scorrano L, Renau-Piqueras J, Alvarez J, Satrústegui J, Palau F. Silencing of the Charcot-Marie-Tooth disease-associated gene GDAP1 induces abnormal mitochondrial distribution and affects Ca2+ homeostasis by reducing store-operated Ca2+ entry. Neurobiol Dis 2013; 55:140-51. [PMID: 23542510 DOI: 10.1016/j.nbd.2013.03.010] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Revised: 03/04/2013] [Accepted: 03/19/2013] [Indexed: 11/25/2022] Open
Abstract
GDAP1 is an outer mitochondrial membrane protein that acts as a regulator of mitochondrial dynamics. Mutations of the GDAP1 gene cause Charcot-Marie-Tooth (CMT) neuropathy. We show that GDAP1 interacts with the vesicle-organelle trafficking proteins RAB6B and caytaxin, which suggests that GDAP1 may participate in the mitochondrial movement within the cell. GDAP1 silencing in the SH-SY5Y cell line induces abnormal distribution of the mitochondrial network, reduces the contact between mitochondria and endoplasmic reticulum (ER) and alters the mobilization of mitochondria towards plasma membrane upon depletion of ER-Ca(2+) stores. GDAP1 silencing does not affect mitochondrial Ca(2+) uptake, ER-Ca(2+), or Ca(2+) flow from ER to mitochondria, but reduces Ca(2+) inflow through store-operated Ca(2+) entry (SOCE) following mobilization of ER-Ca(2+) and SOCE-driven Ca(2+) entry in mitochondria. Our studies suggest that the pathophysiology of GDAP1-related CMT neuropathies may be associated with abnormal distribution and movement of mitochondria throughout cytoskeleton towards the ER and subplasmalemmal microdomains, resulting in a decrease in SOCE activity and impaired SOCE-driven Ca(2+) uptake in mitochondria.
Collapse
Affiliation(s)
- David Pla-Martín
- Laboratory of Genetics and Molecular Medicine, Instituto de Biomedicina de Valencia, CSIC, Valencia, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Llorente-Folch I, Sahún I, Contreras L, Casarejos MJ, Grau JM, Saheki T, Mena MA, Satrústegui J, Dierssen M, Pardo B. AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway. J Neurochem 2013; 124:347-62. [PMID: 23216354 DOI: 10.1111/jnc.12096] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2012] [Revised: 10/09/2012] [Accepted: 11/05/2012] [Indexed: 12/21/2022]
Abstract
The mitochondrial transporter of aspartate-glutamate Aralar/AGC1 is a regulatory component of the malate-aspartate shuttle. Aralar deficiency in mouse and human causes a shutdown of brain shuttle activity and global cerebral hypomyelination. A lack of neurofilament-labeled processes is detected in the cerebral cortex, but whether different types of neurons are differentially affected by Aralar deficiency is still unknown. We have now found that Aralar-knockout (Aralar-KO) post-natal mice show hyperactivity, anxiety-like behavior, and hyperreactivity with a decrease of dopamine (DA) in terminal-rich regions. The striatum is the brain region most affected in terms of size, amino acid and monoamine content. We find a decline in vesicular monoamine transporter-2 (VMAT2) levels associated with increased DA metabolism through MAO activity (DOPAC/DA ratio) in Aralar-KO striatum. However, no decrease in DA or in the number of nigral tyrosine hydroxylase-positive cells was detected in Aralar-KO brainstem. Adult Aralar-hemizygous mice presented also increased DOPAC/DA ratio in striatum and enhanced sensitivity to amphetamine. Our results suggest that Aralar deficiency causes a fall in GSH/GSSG ratio and VMAT2 in striatum that might be related to a failure to produce mitochondrial NADH and to an increase of reactive oxygen species (ROS) in the cytosol. The results indicate that the nigrostriatal dopaminergic system is a target of Aralar deficiency.
Collapse
Affiliation(s)
- Irene Llorente-Folch
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, and CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Amigo I, Traba J, González-Barroso MM, Rueda CB, Fernández M, Rial E, Sánchez A, Satrústegui J, Del Arco A. Glucagon regulation of oxidative phosphorylation requires an increase in matrix adenine nucleotide content through Ca2+ activation of the mitochondrial ATP-Mg/Pi carrier SCaMC-3. J Biol Chem 2013; 288:7791-7802. [PMID: 23344948 DOI: 10.1074/jbc.m112.409144] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
It has been known for a long time that mitochondria isolated from hepatocytes treated with glucagon or Ca(2+)-mobilizing agents such as phenylephrine show an increase in their adenine nucleotide (AdN) content, respiratory activity, and calcium retention capacity (CRC). Here, we have studied the role of SCaMC-3/slc25a23, the mitochondrial ATP-Mg/Pi carrier present in adult mouse liver, in the control of mitochondrial AdN levels and respiration in response to Ca(2+) signals as a candidate target of glucagon actions. With the use of SCaMC-3 knock-out (KO) mice, we have found that the carrier is responsible for the accumulation of AdNs in liver mitochondria in a strictly Ca(2+)-dependent way with an S0.5 for Ca(2+) activation of 3.3 ± 0.9 μm. Accumulation of matrix AdNs allows a SCaMC-3-dependent increase in CRC. In addition, SCaMC-3-dependent accumulation of AdNs is required to acquire a fully active state 3 respiration in AdN-depleted liver mitochondria, although further accumulation of AdNs is not followed by increases in respiration. Moreover, glucagon addition to isolated hepatocytes increases oligomycin-sensitive oxygen consumption and maximal respiratory rates in cells derived from wild type, but not SCaMC-3-KO mice and glucagon administration in vivo results in an increase in AdN content, state 3 respiration and CRC in liver mitochondria in wild type but not in SCaMC-3-KO mice. These results show that SCaMC-3 is required for the increase in oxidative phosphorylation observed in liver mitochondria in response to glucagon and Ca(2+)-mobilizing agents, possibly by allowing a Ca(2+)-dependent accumulation of mitochondrial AdNs and matrix Ca(2+), events permissive for other glucagon actions.
Collapse
Affiliation(s)
- Ignacio Amigo
- Departmento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-CSIC; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER) 28049 Madrid
| | - Javier Traba
- Departmento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-CSIC; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER) 28049 Madrid
| | - M Mar González-Barroso
- Departamento de Medicina Celular y Molecular, Centro de Investigaciones Biológicas (CIB), Consejo Superior de Investigaciones Científicas 28040 Madrid
| | - Carlos B Rueda
- Departmento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-CSIC; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER) 28049 Madrid
| | - Margarita Fernández
- Departamento de Bioquímica y Biología Molecular II, Facultad de Farmacia, Universidad Complutense de Madrid 28040 Madrid
| | - Eduardo Rial
- Departamento de Medicina Celular y Molecular, Centro de Investigaciones Biológicas (CIB), Consejo Superior de Investigaciones Científicas 28040 Madrid
| | - Aránzazu Sánchez
- Departamento de Bioquímica y Biología Molecular II, Facultad de Farmacia, Universidad Complutense de Madrid 28040 Madrid
| | - Jorgina Satrústegui
- Departmento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-CSIC; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER) 28049 Madrid.
| | - Araceli Del Arco
- Área de Bioquímica, Centro Regional de Investigaciones Biomédicas, Facultad de Ciencias Ambientales y Bioquímica, Universidad de Castilla La Mancha (UCLM), Avda. Carlos III s/n, Toledo 45071, Spain.
| |
Collapse
|
24
|
Ramos M, Pardo B, Llorente-Folch I, Saheki T, del Arco A, Satrústegui J. Deficiency of the mitochondrial transporter of aspartate/glutamate aralar/AGC1 causes hypomyelination and neuronal defects unrelated to myelin deficits in mouse brain. J Neurosci Res 2011; 89:2008-17. [DOI: 10.1002/jnr.22639] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2010] [Revised: 01/31/2011] [Accepted: 02/08/2011] [Indexed: 12/24/2022]
|
25
|
Traba J, Satrústegui J, del Arco A. Adenine nucleotide transporters in organelles: novel genes and functions. Cell Mol Life Sci 2011; 68:1183-206. [PMID: 21207102 DOI: 10.1007/s00018-010-0612-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2010] [Revised: 11/16/2010] [Accepted: 12/09/2010] [Indexed: 10/18/2022]
Abstract
In eukaryotes, cellular energy in the form of ATP is produced in the cytosol via glycolysis or in the mitochondria via oxidative phosphorylation and, in photosynthetic organisms, in the chloroplast via photophosphorylation. Transport of adenine nucleotides among cell compartments is essential and is performed mainly by members of the mitochondrial carrier family, among which the ADP/ATP carriers are the best known. This work reviews the carriers that transport adenine nucleotides into the organelles of eukaryotic cells together with their possible functions. We focus on novel mechanisms of adenine nucleotide transport, including mitochondrial carriers found in organelles such as peroxisomes, plastids, or endoplasmic reticulum and also mitochondrial carriers found in the mitochondrial remnants of many eukaryotic parasites of interest. The extensive repertoire of adenine nucleotide carriers highlights an amazing variety of new possible functions of adenine nucleotide transport across eukaryotic organelles.
Collapse
Affiliation(s)
- Javier Traba
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, CIBER de Enfermedades Raras, Universidad Autónoma de Madrid, Madrid, Spain.
| | | | | |
Collapse
|
26
|
Pardo B, Rodrigues TB, Contreras L, Garzón M, Llorente-Folch I, Kobayashi K, Saheki T, Cerdan S, Satrústegui J. Brain glutamine synthesis requires neuronal-born aspartate as amino donor for glial glutamate formation. J Cereb Blood Flow Metab 2011; 31:90-101. [PMID: 20736955 PMCID: PMC3049464 DOI: 10.1038/jcbfm.2010.146] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The glutamate-glutamine cycle faces a drain of glutamate by oxidation, which is balanced by the anaplerotic synthesis of glutamate and glutamine in astrocytes. De novo synthesis of glutamate by astrocytes requires an amino group whose origin is unknown. The deficiency in Aralar/AGC1, the main mitochondrial carrier for aspartate-glutamate expressed in brain, results in a drastic fall in brain glutamine production but a modest decrease in brain glutamate levels, which is not due to decreases in neuronal or synaptosomal glutamate content. In vivo (13)C nuclear magnetic resonance labeling with (13)C(2)acetate or (1-(13)C) glucose showed that the drop in brain glutamine is due to a failure in glial glutamate synthesis. Aralar deficiency induces a decrease in aspartate content, an increase in lactate production, and lactate-to-pyruvate ratio in cultured neurons but not in cultured astrocytes, indicating that Aralar is only functional in neurons. We find that aspartate, but not other amino acids, increases glutamate synthesis in both control and aralar-deficient astrocytes, mainly by serving as amino donor. These findings suggest the existence of a neuron-to-astrocyte aspartate transcellular pathway required for astrocyte glutamate synthesis and subsequent glutamine formation. This pathway may provide a mechanism to transfer neuronal-born redox equivalents to mitochondria in astrocytes.
Collapse
Affiliation(s)
- Beatriz Pardo
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, and CIBER de Enfermedades Raras, Universidad Autónoma de Madrid, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Contreras L, Urbieta A, Kobayashi K, Saheki T, Satrústegui J. Low levels of citrin (SLC25A13) expression in adult mouse brain restricted to neuronal clusters. J Neurosci Res 2009; 88:1009-16. [DOI: 10.1002/jnr.22283] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
28
|
Ruiz P, Martinez C, Satrústegui J, Carrascosa JM, Andrés A. P-37: Role of the C-terminal domain of insulin receptor β-subunit in aging: effects of truncation. Exp Clin Endocrinol Diabetes 2009. [DOI: 10.1055/s-0029-1211580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
29
|
Escrivá F, Agote M, Molero JC, Pascual-Leone AM, Andrés A, Satrústegui J, Carrascosa JM. P-96: Changes in insulin-dependent glucose uptake by specific tissues of the aged Wistar rat. Exp Clin Endocrinol Diabetes 2009. [DOI: 10.1055/s-0029-1211641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
30
|
Traba J, Satrústegui J, del Arco A. Transport of adenine nucleotides in the mitochondria of Saccharomyces cerevisiae: interactions between the ADP/ATP carriers and the ATP-Mg/Pi carrier. Mitochondrion 2009; 9:79-85. [PMID: 19460304 DOI: 10.1016/j.mito.2009.01.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2008] [Revised: 10/09/2008] [Accepted: 01/05/2009] [Indexed: 01/09/2023]
Abstract
The ADP/ATP and ATP-Mg/Pi carriers are widespread among eukaryotes and constitute two systems to transport adenine nucleotides in mitochondria. ADP/ATP carriers carry out an electrogenic exchange of ADP for ATP essential for oxidative phosphorylation, whereas ATP-Mg/Pi carriers perform an electroneutral exchange of ATP-Mg for phosphate and are able to modulate the net content of adenine nucleotides in mitochondria. The functional interplay between both carriers has been shown to modulate viability in Saccharomyces cerevisiae. The simultaneous absence of both carriers is lethal. In the light of the new evidence we suggest that, in addition to exchange of cytosolic ADP for mitochondrial ATP, the specific function of the ADP/ATP carriers required for respiration, both transporters have a second function, which is the import of cytosolic ATP in mitochondria. The participation of these carriers in the generation of mitochondrial membrane potential is discussed. Both are necessary for the function of the mitochondrial protein import and assembly systems, which are the only essential mitochondrial functions in S. cerevisiae.
Collapse
Affiliation(s)
- Javier Traba
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, UAM-CSIC, Universidad Autónoma, CIBER de Enfermedades Raras, c/Nicolas Cabrera 1, 28049 Madrid, Spain.
| | | | | |
Collapse
|
31
|
Contreras L, Satrústegui J. Calcium signaling in brain mitochondria: interplay of malate aspartate NADH shuttle and calcium uniporter/mitochondrial dehydrogenase pathways. J Biol Chem 2009; 284:7091-9. [PMID: 19129175 DOI: 10.1074/jbc.m808066200] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Ca2+ signaling in mitochondria has been mainly attributed to Ca2+ entry to the matrix through the Ca2+ uniporter and activation of mitochondrial matrix dehydrogenases. However, mitochondria can also sense increases in cytosolic Ca2+ through a mechanism that involves the aspartate-glutamate carriers, extramitochondrial Ca2+ activation of the NADH malate-aspartate shuttle (MAS). Both pathways are linked through the shared substrate alpha-ketoglutarate (alphaKG). Here we have studied the interplay between the two pathways under conditions of Ca2+ activation. We show that alphaKG becomes limiting when Ca2+ enters in brain or heart mitochondria, but not liver mitochondria, resulting in a drop in alphaKG efflux through the oxoglutarate carrier and in a drop in MAS activity. Inhibition of alphaKG efflux and MAS activity by matrix Ca2+ in brain mitochondria was fully reversible upon Ca2+ efflux. Because of their differences in cytosolic calcium concentration requirements, the MAS and Ca2+ uniporter-mitochondrial dehydrogenase pathways are probably sequentially activated during a Ca2+ transient, and the inhibition of MAS at the center of the transient may provide an explanation for part of the increase in lactate observed in the stimulated brain in vivo.
Collapse
Affiliation(s)
- Laura Contreras
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-CSIC and CIBER de Enfermedades Raras, 28049 Madrid, Spain
| | | |
Collapse
|
32
|
Mármol P, Pardo B, Wiederkehr A, Del Arco A, Wollheim CB, Satrústegui J. Requirement for aralar and its Ca2+-binding sites in Ca2+ signal transduction in mitochondria from INS-1 clonal beta-cells. J Biol Chem 2008; 284:515-524. [PMID: 18996845 DOI: 10.1074/jbc.m806729200] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Aralar, the mitochondrial aspartate-glutamate carrier present in beta-cells, is a component of the malate-aspartate NADH shuttle (MAS). MAS is activated by Ca2+ in mitochondria from tissues with aralar as the only AGC isoform with an S0.5 of approximately 300 nm. We have studied the role of aralar and its Ca2+-binding EF-hand motifs in glucose-induced mitochondrial NAD(P)H generation by two-photon microscopy imaging in INS-1 beta-cells lacking aralar or expressing aralar mutants blocked for Ca2+ binding. Aralar knock-down in INS-1 beta-cell lines resulted in undetectable levels of aralar protein and complete loss of MAS activity in isolated mitochondria and in a 25% decrease in glucose-stimulated insulin secretion. MAS activity in mitochondria from INS-1 cells was activated 2-3-fold by extramitochondrial Ca2+, whereas aralar mutants were Ca2+ insensitive. In Ca2+-free medium, glucose-induced increases in mitochondrial NAD(P)H were small (1.3-fold) and unchanged regardless of the lack of aralar. In the presence of 1.5 mm Ca2+, glucose induced robust increases in mitochondrial NAD(P)H (approximately 2-fold) in cell lines with wild-type or mutant aralar. There was a approximately 20% reduction in NAD(P)H response in cells lacking aralar, illustrating the importance of MAS in glucose action. When small Ca2+ signals that resulted in extremely small mitochondrial Ca2+ transients were induced in the presence of glucose, the rise in mitochondrial NAD(P)H was maintained in cells with wild-type aralar but was reduced by approximately 50% in cells lacking or expressing mutant aralar. These results indicate that 1) glucose-induced activation of MAS requires Ca2+ potentiation; 2) Ca2+ activation of MAS represents a larger fraction of glucose-induced mitochondrial NAD(P)H production under conditions where suboptimal Ca2+ signals are associated with a glucose challenge (50 versus 20%, respectively); 3) inactivation of EF-hand motifs in aralar prevents activation of MAS by small Ca2+ signals. The results suggest a possible role for aralar and MAS in priming the beta-cell by Ca2+-mobilizing neurotransmitter or hormones.
Collapse
Affiliation(s)
- Patricia Mármol
- Departamento de Biología Molecular and Centro de Biología Molecular Severo Ochoa CSIC-UAM, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma, 28049 Madrid, Spain, the Area de Bioquímica, Centro Regional de Investigaciones Biomádicas (CRIB), Facultad de Ciencias del Medio Ambiente, Universidad de Castilla-La Mancha, 48071 Toledo, Spain, and the Department of Cell Physiology and Metabolism, University Medical Center, CH-1211 Geneva, Switzerland
| | - Beatriz Pardo
- Departamento de Biología Molecular and Centro de Biología Molecular Severo Ochoa CSIC-UAM, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma, 28049 Madrid, Spain, the Area de Bioquímica, Centro Regional de Investigaciones Biomádicas (CRIB), Facultad de Ciencias del Medio Ambiente, Universidad de Castilla-La Mancha, 48071 Toledo, Spain, and the Department of Cell Physiology and Metabolism, University Medical Center, CH-1211 Geneva, Switzerland
| | - Andreas Wiederkehr
- Departamento de Biología Molecular and Centro de Biología Molecular Severo Ochoa CSIC-UAM, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma, 28049 Madrid, Spain, the Area de Bioquímica, Centro Regional de Investigaciones Biomádicas (CRIB), Facultad de Ciencias del Medio Ambiente, Universidad de Castilla-La Mancha, 48071 Toledo, Spain, and the Department of Cell Physiology and Metabolism, University Medical Center, CH-1211 Geneva, Switzerland
| | - Araceli Del Arco
- Departamento de Biología Molecular and Centro de Biología Molecular Severo Ochoa CSIC-UAM, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma, 28049 Madrid, Spain, the Area de Bioquímica, Centro Regional de Investigaciones Biomádicas (CRIB), Facultad de Ciencias del Medio Ambiente, Universidad de Castilla-La Mancha, 48071 Toledo, Spain, and the Department of Cell Physiology and Metabolism, University Medical Center, CH-1211 Geneva, Switzerland; Departamento de Biología Molecular and Centro de Biología Molecular Severo Ochoa CSIC-UAM, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma, 28049 Madrid, Spain, the Area de Bioquímica, Centro Regional de Investigaciones Biomádicas (CRIB), Facultad de Ciencias del Medio Ambiente, Universidad de Castilla-La Mancha, 48071 Toledo, Spain, and the Department of Cell Physiology and Metabolism, University Medical Center, CH-1211 Geneva, Switzerland
| | - Claes B Wollheim
- Departamento de Biología Molecular and Centro de Biología Molecular Severo Ochoa CSIC-UAM, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma, 28049 Madrid, Spain, the Area de Bioquímica, Centro Regional de Investigaciones Biomádicas (CRIB), Facultad de Ciencias del Medio Ambiente, Universidad de Castilla-La Mancha, 48071 Toledo, Spain, and the Department of Cell Physiology and Metabolism, University Medical Center, CH-1211 Geneva, Switzerland
| | - Jorgina Satrústegui
- Departamento de Biología Molecular and Centro de Biología Molecular Severo Ochoa CSIC-UAM, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma, 28049 Madrid, Spain, the Area de Bioquímica, Centro Regional de Investigaciones Biomádicas (CRIB), Facultad de Ciencias del Medio Ambiente, Universidad de Castilla-La Mancha, 48071 Toledo, Spain, and the Department of Cell Physiology and Metabolism, University Medical Center, CH-1211 Geneva, Switzerland.
| |
Collapse
|
33
|
Traba J, Froschauer EM, Wiesenberger G, Satrústegui J, Del Arco A. Yeast mitochondria import ATP through the calcium-dependent ATP-Mg/Pi carrier Sal1p, and are ATP consumers during aerobic growth in glucose. Mol Microbiol 2008; 69:570-85. [PMID: 18485069 DOI: 10.1111/j.1365-2958.2008.06300.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Sal1p, a novel Ca2+-dependent ATP-Mg/Pi carrier, is essential in yeast lacking all adenine nucleotide translocases. By targeting luciferase to the mitochondrial matrix to monitor mitochondrial ATP levels, we show in isolated mitochondria that both ATP-Mg and free ADP are taken up by Sal1p with a K(m) of 0.20 +/- 0.03 mM and 0.28 +/- 0.06 mM respectively. Nucleotide transport along Sal1p is strictly Ca2+ dependent. Ca2+ increases the V(max) with a S(0.5) of 15 muM, and no changes in the K(m) for ATP-Mg. Glucose sensing in yeast generates Ca2+ transients involving Ca2+ influx from the external medium. We find that carbon-deprived cells respond to glucose with an immediate increase in mitochondrial ATP levels which is not observed in the presence of EGTA or in Sal1p-deficient cells. Moreover, we now report that during normal aerobic growth on glucose, yeast mitochondria import ATP from the cytosol and hydrolyse it through H+-ATP synthase. We identify two pathways for ATP uptake in mitochondria, the ADP/ATP carriers and Sal1p. Thus, during exponential growth on glucose, mitochondria are ATP consumers, as those from cells growing in anaerobic conditions or deprived of mitochondrial DNA which depend on cytosolic ATP and mitochondrial ATPase working in reverse to generate a mitochondrial membrane potential. In conclusion, the results show that growth on glucose requires ATP hydrolysis in mitochondria and recruits Sal1p as a Ca2+-dependent mechanism to import ATP-Mg from the cytosol. Whether this mechanism is used under similar settings in higher eukaryotes is an open question.
Collapse
Affiliation(s)
- Javier Traba
- Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, CIBER de Enfermedades Raras (CIBERER), Universidad Autónoma, Madrid, Spain
| | | | | | | | | |
Collapse
|
34
|
Satrústegui J, Contreras L, Ramos M, Marmol P, del Arco A, Saheki T, Pardo B. Role of aralar, the mitochondrial transporter of aspartate-glutamate, in brain N-acetylaspartate formation and Ca(2+) signaling in neuronal mitochondria. J Neurosci Res 2008; 85:3359-66. [PMID: 17497669 DOI: 10.1002/jnr.21299] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Aralar, the Ca(2+)-dependent mitochondrial aspartate-glutamate carrier expressed in brain and skeletal muscle, is a member of the malate-aspartate NADH shuttle. Disrupting the gene for aralar, SLC25a12, in mice has enabled the discovery of two new roles of this carrier. On the one hand, it is required for synthesis of brain aspartate and N-acetylaspartate, a neuron-born metabolite that supplies acetate for myelin lipid synthesis; and on the other, it is essential for the transmission of small Ca(2+) signals to mitochondria via an increase in mitochondrial NADH.
Collapse
Affiliation(s)
- Jorgina Satrústegui
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Facultad de Ciencias, Universidad Autónoma, 28049, Cantoblanco, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
35
|
Contreras L, Gomez-Puertas P, Iijima M, Kobayashi K, Saheki T, Satrústegui J. Ca2+ Activation kinetics of the two aspartate-glutamate mitochondrial carriers, aralar and citrin: role in the heart malate-aspartate NADH shuttle. J Biol Chem 2007; 282:7098-106. [PMID: 17213189 DOI: 10.1074/jbc.m610491200] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Ca(2+) regulation of the Ca(2+) binding mitochondrial carriers for aspartate/glutamate (AGCs) is provided by their N-terminal extensions, which face the intermembrane space. The two mammalian AGCs, aralar and citrin, are members of the malate-aspartate NADH shuttle. We report that their N-terminal extensions contain up to four pairs of EF-hand motifs plus a single vestigial EF-hand, and have no known homolog. Aralar and citrin contain one fully canonical EF-hand pair and aralar two additional half-pairs, in which a single EF-hand is predicted to bind Ca(2+). Shuttle activity in brain or skeletal muscle mitochondria, which contain aralar as the major AGC, is activated by Ca(2+) with S(0.5) values of 280-350 nm; higher than those obtained in liver mitochondria (100-150 nm) that contain citrin as the major AGC. We have used aralar- and citrin-deficient mice to study the role of the two isoforms in heart, which expresses both AGCs. The S(0.5) for Ca(2+) activation of the shuttle in heart mitochondria is about 300 nm, and it remains essentially unchanged in citrin-deficient mice, although it undergoes a drastic reduction to about 100 nm in aralar-deficient mice. Therefore, aralar and citrin, when expressed as single isoforms in heart, confer differences in Ca(2+) activation of shuttle activity, probably associated with their structural differences. In addition, the results reveal that the two AGCs fully account for shuttle activity in mouse heart mitochondria and that no other glutamate transporter can replace the AGCs in this pathway.
Collapse
Affiliation(s)
- Laura Contreras
- Departamento de Biología Molecular, Universidad Autónoma de Madrid, C.S.I.C., 28049 Madrid, Spain
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
Ca2+signaling in mitochondria is important to tune mitochondrial function to a variety of extracellular stimuli. The main mechanism is Ca2+entry in mitochondria via the Ca2+uniporter followed by Ca2+activation of three dehydrogenases in the mitochondrial matrix. This results in increases in mitochondrial NADH/NAD ratios and ATP levels and increased substrate uptake by mitochondria. We review evidence gathered more than 20 years ago and recent work indicating that substrate uptake, mitochondrial NADH/NAD ratios, and ATP levels may be also activated in response to cytosolic Ca2+signals via a mechanism that does not require the entry of Ca2+in mitochondria, a mechanism depending on the activity of Ca2+-dependent mitochondrial carriers (CaMC). CaMCs fall into two groups, the aspartate-glutamate carriers (AGC) and the ATP-Mg/Picarriers, also named SCaMC (for short CaMC). The two mammalian AGCs, aralar and citrin, are members of the malate-aspartate NADH shuttle, and citrin, the liver AGC, is also a member of the urea cycle. Both types of CaMCs are activated by Ca2+in the intermembrane space and function together with the Ca2+uniporter in decoding the Ca2+signal into a mitochondrial response.
Collapse
Affiliation(s)
- Jorgina Satrústegui
- Departamento de Biología Molecular Centro de Biología Molecular "Severo Ochoa" UAM-CSIC, Facultad de Ciencias, Universidad Autónoma, Madrid, Spain.
| | | | | |
Collapse
|
37
|
Cavero S, Traba J, Del Arco A, Satrústegui J. The calcium-dependent ATP-Mg/Pi mitochondrial carrier is a target of glucose-induced calcium signalling in Saccharomyces cerevisiae. Biochem J 2006; 392:537-44. [PMID: 16111475 PMCID: PMC1316293 DOI: 10.1042/bj20050806] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Sal1p is a mitochondrial protein that belongs to the SCaMC (short calcium-binding mitochondrial carrier) subfamily of mitochondrial carriers. The presence of calcium-binding motifs facing the extramitochondrial space allows the regulation of the transport activity of these carriers by cytosolic calcium and provides a new mechanism to transduce calcium signals in mitochondria without the requirement of calcium entry in the organelle. We have studied its transport activity, finding that it is a carboxyatractyloside-resistant ATP-Mg carrier. Mitochondria from a disruption mutant of SAL1 have a 50% reduction in the uptake of ATP. We have also found a clear stimulation of ATP-transport activity by calcium, with an S(0.5) of approx. 30 microM. Our results also suggest that Sal1p is a target of the glucose-induced calcium signal which is non-essential in wild-type cells, but becomes essential for transport of ATP into mitochondria in yeast lacking ADP/ATP translocases.
Collapse
Affiliation(s)
- Santiago Cavero
- *Departamento de Biología Molecular, Centro de Biología Molecular “Severo Ochoa” UAM-CSIC, Facultad de Ciencias, Universidad Autónoma, 28049 Madrid, Spain
| | - Javier Traba
- *Departamento de Biología Molecular, Centro de Biología Molecular “Severo Ochoa” UAM-CSIC, Facultad de Ciencias, Universidad Autónoma, 28049 Madrid, Spain
| | - Araceli Del Arco
- *Departamento de Biología Molecular, Centro de Biología Molecular “Severo Ochoa” UAM-CSIC, Facultad de Ciencias, Universidad Autónoma, 28049 Madrid, Spain
- †Área de Bioquímica, Centro Regional de Investigaciones Biomédicas (CRIB), Facultad de Ciencias del Medio Ambiente, Universidad de Castilla-La Mancha, Av. Carlos III s/n, 45071 Toledo, Spain
| | - Jorgina Satrústegui
- *Departamento de Biología Molecular, Centro de Biología Molecular “Severo Ochoa” UAM-CSIC, Facultad de Ciencias, Universidad Autónoma, 28049 Madrid, Spain
- To whom correspondence should be addressed (email )
| |
Collapse
|
38
|
Abstract
The transport of metabolites, nucleotides and cofactors across the mitochondrial inner membrane is performed by members of mitochondrial carrier family (MCF). These proteins share marked structural features that have made feasible the functional characterization of numerous MCs in the last years. The MCs responsible for transport activities in mitochondria known for decades such as glutamate uptake or ATP-Mg/Pi exchange have recently been identified as well as novel carriers such as those involved in S-adenosylmethionine or thiamine pyrophosphate uptake. Here, after a brief review of the novel data on structural characteristics and import mechanisms of MCF members, we present an exhaustive compilation of human MC sequences, including previously characterized carriers, together with their respective Saccharomyces cerevisiae orthologues, ordered according to the phylogenetic analysis of el Moualij and co-workers [Yeast (1997) 13: 573-581]. We have detected the existence of at least 49 human MC sequences, including those of yet unknown function. An overview of novel MCF members functionally characterized in recent years in mammals and in yeast genomes is presented.
Collapse
Affiliation(s)
- A Del Arco
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Facultad de Ciencias, Universidad Autónoma, 28049, Madrid, Spain
| | | |
Collapse
|
39
|
Pardo B, Contreras L, Serrano A, Ramos M, Kobayashi K, Iijima M, Saheki T, Satrústegui J. Essential role of aralar in the transduction of small Ca2+ signals to neuronal mitochondria. J Biol Chem 2005; 281:1039-47. [PMID: 16269409 DOI: 10.1074/jbc.m507270200] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Aralar, the neuronal Ca(2+)-binding mitochondrial aspartate-glutamate carrier, has Ca(2+) binding domains facing the extramitochondrial space and functions in the malate-aspartate NADH shuttle (MAS). Here we showed that MAS activity in brain mitochondria is stimulated by extramitochondrial Ca(2+) with an S(0.5) of 324 nM. By employing primary neuronal cultures from control and aralar-deficient mice and NAD(P)H imaging with two-photon excitation microscopy, we showed that lactate utilization involves a substantial transfer of NAD(P)H to mitochondria in control but not aralar-deficient neurons, in agreement with the lack of MAS activity associated with aralar deficiency. The increase in mitochondrial NAD(P)H was greatly potentiated by large [Ca(2+)](i) signals both in control and aralar-deficient neurons, showing that these large signals activate the Ca(2+) uniporter and mitochondrial dehydrogenases but not MAS activity. On the other hand, small [Ca(2+)](i) signals potentiate the increase in mitochondrial NAD(P)H only in control but not in aralar-deficient neurons. We concluded that neuronal MAS activity is selectively activated by small Ca(2+) signals that fall below the activation range of the Ca(2+) uniporter and plays an essential role in mitochondrial Ca(2+) signaling.
Collapse
Affiliation(s)
- Beatriz Pardo
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Jalil MA, Begum L, Contreras L, Pardo B, Iijima M, Li MX, Ramos M, Marmol P, Horiuchi M, Shimotsu K, Nakagawa S, Okubo A, Sameshima M, Isashiki Y, Del Arco A, Kobayashi K, Satrústegui J, Saheki T. Reduced N-Acetylaspartate Levels in Mice Lacking Aralar, a Brain- and Muscle-type Mitochondrial Aspartate-glutamate Carrier. J Biol Chem 2005; 280:31333-9. [PMID: 15987682 DOI: 10.1074/jbc.m505286200] [Citation(s) in RCA: 122] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Aralar is a mitochondrial calcium-regulated aspartate-glutamate carrier mainly distributed in brain and skeletal muscle, involved in the transport of aspartate from mitochondria to cytosol, and in the transfer of cytosolic reducing equivalents into mitochondria as a member of the malate-aspartate NADH shuttle. In the present study, we describe the characteristics of aralar-deficient (Aralar-/-) mice, generated by a gene-trap method, showing no aralar mRNA and protein, and no detectable malate-aspartate shuttle activity in skeletal muscle and brain mitochondria. Aralar-/- mice were growth-retarded, exhibited generalized tremoring, and had pronounced motor coordination defects along with an impaired myelination in the central nervous system. Analysis of lipid components showed a marked decrease in the myelin lipid galactosyl cerebroside. The content of the myelin lipid precursor, N-acetylaspartate, and that of aspartate are drastically decreased in the brain of Aralar-/- mice. The defect in N-acetylaspartate production was also observed in cell extracts from primary neuronal cultures derived from Aralar-/- mouse embryos. These results show that aralar plays an important role in myelin formation by providing aspartate for the synthesis of N-acetylaspartate in neuronal cells.
Collapse
Affiliation(s)
- Md Abdul Jalil
- Department of Molecular Metabolism and Biochemical Genetics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Aralar1 and citrin were identified as calcium binding aspartate/glutamate carriers (AGC) in mitochondria. The presence of calcium binding motifs facing the extramitochondrial space allows the regulation of the transport activity of these carriers by cytosolic calcium and provides a new mechanism to transduce calcium signals in mitochondria without the requirement of calcium entry in the organelle. We now report the complete characterization of a second subfamily of human calcium binding mitochondrial carriers named SCaMC (short calcium-binding mitochondrial carriers). We have identified three SCaMC genes in the human genome. All code for highly conserved proteins (about 70-80% identity), of about 500 amino acids with a characteristic mitochondrial carrier domain at the C terminus, and an N-terminal extension harboring four EF-hand binding motifs with high similarity to calmodulin. All SCaMC proteins were found to be located exclusively in mitochondria, and their N-terminal extensions were dispensable for the correct mitochondrial targeting of the polypeptides. SCaMC-1 is the human orthologue of the rabbit Efinal protein, which was reported to be located in peroxisomes, and SCaMC-2 is the human orthologue of the rat MCSC protein, described as up-regulated by dexamethasone in AR42J cells. One of the SCaMC genes, SCaMC-2, has four variants generated by alternative splicing, resulting in proteins with a common C terminus but with variations in their N-terminal halves, including the loss of one to three EF-hand motifs. These results make SCaMC one of most complex subfamilies of mitochondrial carriers and suggest that the large number of isoforms and splice variants may confer different calcium sensitivity to the transport activity of these carriers.
Collapse
Affiliation(s)
- Araceli del Arco
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Facultad de Ciencias, Universidad Autónoma, 28049 Madrid, Spain.
| | | |
Collapse
|
42
|
Cavero S, Vozza A, del Arco A, Palmieri L, Villa A, Blanco E, Runswick MJ, Walker JE, Cerdán S, Palmieri F, Satrústegui J. Identification and metabolic role of the mitochondrial aspartate-glutamate transporter in Saccharomyces cerevisiae. Mol Microbiol 2003; 50:1257-69. [PMID: 14622413 DOI: 10.1046/j.1365-2958.2003.03742.x] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The malate-aspartate NADH shuttle in mammalian cells requires the activity of the mitochondrial aspartate-glutamate carrier (AGC). Recently, we identified in man two AGC isoforms, aralar1 and citrin, which are regulated by calcium on the external face of the inner mitochondrial membrane. We have now identified Agc1p as the yeast counterpart of the human AGC. The corresponding gene was overexpressed in bacteria and yeast mitochondria, and the protein was reconstituted in liposomes where it was identified as an aspartate-glutamate transporter from its transport properties. Furthermore, yeast cells lacking Agc1p were unable to grow on acetate and oleic acid, and had reduced levels of valine, ornithine and citrulline; in contrast they grew on ethanol. Expression of the human AGC isoforms can replace the function of Agc1p. However, unlike its human orthologues, yeast Agc1p catalyses both aspartate-glutamate exchange and substrate uniport activities. We conclude that Agc1p performs two metabolic roles in Saccharomyces cerevisiae. On the one hand, it functions as a uniporter to supply the mitochondria with glutamate for nitrogen metabolism and ornithine synthesis. On the other, the Agc1p, as an aspartate-glutamate exchanger, plays a role within the malate-aspartate NADH shuttle which is critical for the growth of yeast on acetate and fatty acids as carbon sources. These results provide strong evidence of the existence of a malate-aspartate NADH shuttle in yeast.
Collapse
Affiliation(s)
- S Cavero
- Departmento Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid-C S I C, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Alvarez G, Ramos M, Ruiz F, Satrústegui J, Bogónez E. Pyruvate protection against beta-amyloid-induced neuronal death: role of mitochondrial redox state. J Neurosci Res 2003; 73:260-9. [PMID: 12836169 DOI: 10.1002/jnr.10648] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The mechanism by which beta-amyloid protein (A beta) causes degeneration in cultured neurons is not completely understood, but several lines of evidence suggest that A beta-mediated neuronal death is associated with an enhanced production of reactive oxygen species (ROS) and oxidative damage. In the present study, we address whether supplementation of glucose-containing culture media with energy substrates, pyruvate plus malate (P/M), protects rat primary neurons from A beta-induced degeneration and death. We found that P/M addition attenuated cell death evoked by beta-amyloid peptides (A beta(25-35) and A beta(1-40)) after 24 hr treatment and that this effect was blocked by alpha-ciano-3-hydroxycinnamate (CIN), suggesting that it requires mitochondrial pyruvate uptake. P/M supply to control and A beta-treated neuronal cultures increases cellular reducing power, as indicated by the ability to reduce the dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The early increases in ROS levels, measured by dichlorofluorescein (DCF) fluorescence, and caspase-3 activity that follow exposure to A beta were notably reduced in the presence of P/M. These results place activation of caspase-3 most likely downstream of oxidative damage to the mitochondria and indicate that mitochondrial NAD(P) redox status plays a central role in the neuroprotective effect of pyruvate. Inhibition of respiratory chain complexes and mitochondrial uncoupling did not block the early increase in ROS levels, suggesting that A beta could initiate oxidative stress by activating a source of ROS that is not accesible to the antioxidant defenses fueled by mitochondrial substrates.
Collapse
Affiliation(s)
- Gema Alvarez
- Centro de Biología Molecular "Severo Ochoa," CSIC-Universidad Autónoma de Madrid, Madrid, Spain
| | | | | | | | | |
Collapse
|
44
|
Ramos M, del Arco A, Pardo B, Martínez-Serrano A, Martínez-Morales JR, Kobayashi K, Yasuda T, Bogónez E, Bovolenta P, Saheki T, Satrústegui J. Developmental changes in the Ca2+-regulated mitochondrial aspartate-glutamate carrier aralar1 in brain and prominent expression in the spinal cord. Brain Res Dev Brain Res 2003; 143:33-46. [PMID: 12763579 DOI: 10.1016/s0165-3806(03)00097-x] [Citation(s) in RCA: 126] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Aralar1 and citrin are two isoforms of the mitochondrial carrier of aspartate-glutamate (AGC), a calcium regulated carrier, which is important in the malate-aspartate NADH shuttle. The expression and cell distribution of aralar1 and citrin in brain cells has been studied during development in vitro and in vivo. Aralar1 is the only isoform expressed in neurons and its levels undergo a marked increase during in vitro maturation, which is higher than the increase in mitochondrial DNA in the same time window. The enrichment in aralar1 per mitochondria during neuronal maturation is associated with a prominent rise in the function of the malate-aspartate NADH shuttle. Paradoxically, during in vivo development of rat or mouse brain there is very little postnatal increase in total aralar1 levels per mitochondria. This is explained by the fact that astrocytes develop postnatally, have aralar1 levels much lower than neurons, and their increase masks that of aralar1. Aralar1 mRNA and protein are widely expressed throughout neuron-rich areas in adult mouse CNS with clear enrichments in sets of neuronal nuclei in the brainstem and, particularly, in the ventral horn of the spinal cord. These aralar1-rich neurons represent a subset of the cytochrome oxidase-rich neurons in the same areas. The presence of aralar1 could reflect a tonic activity of these neurons, which is met by the combination of high malate-aspartate NADH shuttle and respiratory chain activities.
Collapse
Affiliation(s)
- Milagros Ramos
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
del Arco A, Morcillo J, Martínez-Morales JR, Galián C, Martos V, Bovolenta P, Satrústegui J. Expression of the aspartate/glutamate mitochondrial carriers aralar1 and citrin during development and in adult rat tissues. Eur J Biochem 2002; 269:3313-20. [PMID: 12084073 DOI: 10.1046/j.1432-1033.2002.03018.x] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Aralar1 and citrin are members of the subfamily of calcium-binding mitochondrial carriers and correspond to two isoforms of the mitochondrial aspartate/glutamate carrier (AGC). These proteins are activated by Ca2+ acting on the external side of the inner mitochondrial membrane. Although it is known that aralar1 is expressed mainly in skeletal muscle, heart and brain, whereas citrin is present in liver, kidney and heart, the precise tissue distribution of the two proteins in embryonic and adult tissues is largely unknown. We investigated the pattern of expression of aralar1 and citrin in murine embryonic and adult tissues at the mRNA and protein levels. In situ hybridization analysis indicates that both isoforms are expressed strongly in the branchial arches, dermomyotome, limb and tail buds at early embryonic stages. However, citrin was more abundant in the ectodermal components of these structures whereas aralarl had a predominantly mesenchymal localization. The strong expression of citrin in the liver was acquired postnatally, whereas the characteristic expression of aralar1 in skeletal muscle was detected at E18 and that in the heart began early in development (E11) and was preferentially localized to auricular myocardium in late embryonic stages. Aralar1 was also expressed in bone marrow, T-lymphocytes and macrophages, including Kupffer cells in the liver, indicating that this is the major AGC isoform present in the hematopoietic system. Both aralar1 and citrin were expressed in fetal gut and adult stomach, ovary, testis, and pancreas, but only aralar1 is enriched in lung and insulin-secreting beta cells. These results show that aralar1 is expressed in many more tissues than originally believed and is absent from hepatocytes, where citrin is the only AGC isoform present. This explains why citrin deficiency in humans (type II citrullinemia) only affects the liver and suggests that aralar1 may compensate for the lack of citrin in other tissues.
Collapse
Affiliation(s)
- Araceli del Arco
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049-Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
46
|
Alvarez G, Muñoz-Montaño JR, Satrústegui J, Avila J, Bogónez E, Díaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 2002; 4:153-65. [PMID: 12180271 DOI: 10.1034/j.1399-5618.2002.01150.x] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of the beta-amyloid peptide and the hyperphosphorylation of the tau protein, among other features. The most widely accepted hypothesis on the etiopathogenesis of this disease proposes that the aggregates of the beta-amyloid peptide are the main triggers of tau hyperphosphorylation and the subsequent degeneration of affected neurons. In support of this view, fibrillar aggregates of synthetic beta-amyloid peptide induce tau hyperphosphorylation and cell death in cultured neurons. We have previously reported that lithium inhibits tau hyperphosphorylation and also significantly protects cultured neurons from cell death triggered by beta-amyloid peptide. As lithium is a relatively specific inhibitor of glycogen synthase kinase-3 (in comparison with other protein kinases), and other studies also point to a relevant role of this enzyme, we favor the view that glycogen synthase kinase-3 is a crucial element in the pathogenesis of Alzheimer's disease. In our opinion, the possibility of using lithium, or other inhibitors of glycogen synthase kinase-3, in experimental trials aimed to ameliorate neurodegeneration in Alzheimer's disease should be considered.
Collapse
Affiliation(s)
- Gema Alvarez
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Universidad Autónoma de Madrid, Madrid, Spain, 28049
| | | | | | | | | | | |
Collapse
|
47
|
Begum L, Jalil MA, Kobayashi K, Iijima M, Li MX, Yasuda T, Horiuchi M, del Arco A, Satrústegui J, Saheki T. Expression of three mitochondrial solute carriers, citrin, aralar1 and ornithine transporter, in relation to urea cycle in mice. Biochim Biophys Acta 2002; 1574:283-92. [PMID: 11997094 DOI: 10.1016/s0167-4781(01)00376-1] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The present report describes the expression profiles of different tissues and developmental changes of mouse aspartate/glutamate carrier (AGC) genes, Slc25a13 and Slc25a12, and an ornithine transporter gene, Ornt1, in relation to urea cycle enzyme genes, carbamoylphosphate synthetase I (CPS) and argininosuccinate synthetase (ASS). Slc25a13 encodes citrin, recently found to be deficient in adult-onset type II citrullinemia and to function as AGC together with its isoform and product of Slc25a12, aralar1. Citrin was broadly distributed, but mainly in the liver, kidney and heart. Aralar1 was expressed in diaphragm, skeletal muscle, heart, brain and kidney, but not in the liver. These distribution profiles are different from the restricted of Ornt1, ASS and CPS. Citrin, ASS, CPS and Ornt1 showed similar patterns of developmental changes in the liver and small intestine, where they play a role in urea and arginine synthesis. Dietary, hormonal and physical manipulations caused varied changes of CPS, ASS and Ornt1 in the liver, but the change of citrin was not so marked as that of the others. Analysis using RT-PCR and restriction enzyme digestion revealed that the ornithine transporter most expressed is Ornt1, although Ornt2 is detectable at a minute level. All these results suggest that citrin as AGC plays a role in urea synthesis as well as many fundamental metabolic pathways in the liver, and shares metabolic functions with aralar1 in other tissues, and that Ornt1 is an important component in urea synthesis in the liver and in arginine synthesis in the small intestine during the neonatal period.
Collapse
Affiliation(s)
- Laila Begum
- Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, 890-8520, Kagoshima, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Cruz F, Villalba M, García-Espinosa MA, Ballesteros P, Bogónez E, Satrústegui J, Cerdán S. Intracellular compartmentation of pyruvate in primary cultures of cortical neurons as detected by (13)C NMR spectroscopy with multiple (13)C labels. J Neurosci Res 2001; 66:771-81. [PMID: 11746401 DOI: 10.1002/jnr.10048] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The intracellular compartmentation of pyruvate in primary cultures of cortical neurons was investigated by high resolution (13)C NMR using mixtures of different pyruvate precursors conveniently labeled with (13)C or unlabeled. Cells were incubated with 1-5 mM (1-(13)C, 1,2-(13)C(2) or U-(13)C(6)) glucose only or with mixtures containing 1.5 mM (1-(13)C or U-(13)C(6)) glucose, 0.25-2.5 mM (2-(13)C or 3-(13)C) pyruvate and 1 mM malate. Extracts from cells and incubation media were analyzed by (13)C NMR to determine the relative contributions of the different precursors to the intracellular pyruvate pool. When ((13)C) glucose was used as the sole substrate fractional (13)C enrichments and (13)C isotopomer populations in lactate and glutamate carbons were compatible with a unique intracellular pool of pyruvate. When mixtures of ((13)C) glucose, ((13)C) pyruvate and malate were used, however, the fractional (13)C enrichments of the C2 and C3 carbons of lactate were higher than those of the C2 and C3 carbons of alanine and depicted a different (13)C isotopomer distribution. Moreover, neurons incubated with 1 mM (1,2-(13)C(2)) glucose and 0.25-5 mM (3-(13)C) pyruvate produced exclusively (3-(13)C) lactate, revealing that extracellular pyruvate is the unique precursor of lactate under these conditions. These results reveal the presence of two different pools of intracellular pyruvate; one derived from extracellular pyruvate, used mainly for lactate and alanine production and one derived from glucose used primarily for oxidation. A red-ox switch using the cytosolic NAD(+)/NADH ratio is proposed to modulate glycolytic flux, controlling which one of the two pyruvate pools is metabolized in the tricarboxylic acid cycle when substrates more oxidized or reduced than glucose are used.
Collapse
Affiliation(s)
- F Cruz
- Instituto de Investigaciones Biomédicas Alberto Sols, C.S.I.C./U.A.M., c/ Arturo Duperier 4, Madrid 28029, Spain
| | | | | | | | | | | | | |
Collapse
|
49
|
Palmieri L, Pardo B, Lasorsa F, del Arco A, Kobayashi K, Iijima M, Runswick M, Walker J, Saheki T, Satrústegui J, Palmieri F. Citrin and aralar1 are Ca(2+)-stimulated aspartate/glutamate transporters in mitochondria. EMBO J 2001; 20:5060-9. [PMID: 11566871 PMCID: PMC125626 DOI: 10.1093/emboj/20.18.5060] [Citation(s) in RCA: 360] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The mitochondrial aspartate/glutamate carrier catalyzes an important step in both the urea cycle and the aspartate/malate NADH shuttle. Citrin and aralar1 are homologous proteins belonging to the mitochondrial carrier family with EF-hand Ca(2+)-binding motifs in their N-terminal domains. Both proteins and their C-terminal domains were overexpressed in Escherichia coli, reconstituted into liposomes and shown to catalyze the electrogenic exchange of aspartate for glutamate and a H(+). Overexpression of the carriers in transfected human cells increased the activity of the malate/aspartate NADH shuttle. These results demonstrate that citrin and aralar1 are isoforms of the hitherto unidentified aspartate/glutamate carrier and explain why mutations in citrin cause type II citrullinemia in humans. The activity of citrin and aralar1 as aspartate/glutamate exchangers was stimulated by Ca(2+) on the external side of the inner mitochondrial membrane, where the Ca(2+)-binding domains of these proteins are localized. These results show that the aspartate/glutamate carrier is regulated by Ca(2+) through a mechanism independent of Ca(2+) entry into mitochondria, and suggest a novel mechanism of Ca(2+) regulation of the aspartate/malate shuttle.
Collapse
Affiliation(s)
| | - B. Pardo
- Department of Pharmaco-Biology, University of Bari, Via Orabona 4, 70125 Bari, Italy,
Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Facultad de Ciencias del Medio Ambiente, Universidad de Castilla La Mancha, Toledo, Spain, Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan and The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge CB2 2XY, UK Corresponding author e-mail:
| | | | - A. del Arco
- Department of Pharmaco-Biology, University of Bari, Via Orabona 4, 70125 Bari, Italy,
Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Facultad de Ciencias del Medio Ambiente, Universidad de Castilla La Mancha, Toledo, Spain, Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan and The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge CB2 2XY, UK Corresponding author e-mail:
| | - K. Kobayashi
- Department of Pharmaco-Biology, University of Bari, Via Orabona 4, 70125 Bari, Italy,
Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Facultad de Ciencias del Medio Ambiente, Universidad de Castilla La Mancha, Toledo, Spain, Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan and The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge CB2 2XY, UK Corresponding author e-mail:
| | - M. Iijima
- Department of Pharmaco-Biology, University of Bari, Via Orabona 4, 70125 Bari, Italy,
Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Facultad de Ciencias del Medio Ambiente, Universidad de Castilla La Mancha, Toledo, Spain, Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan and The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge CB2 2XY, UK Corresponding author e-mail:
| | - M.J. Runswick
- Department of Pharmaco-Biology, University of Bari, Via Orabona 4, 70125 Bari, Italy,
Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Facultad de Ciencias del Medio Ambiente, Universidad de Castilla La Mancha, Toledo, Spain, Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan and The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge CB2 2XY, UK Corresponding author e-mail:
| | - J.E. Walker
- Department of Pharmaco-Biology, University of Bari, Via Orabona 4, 70125 Bari, Italy,
Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Facultad de Ciencias del Medio Ambiente, Universidad de Castilla La Mancha, Toledo, Spain, Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan and The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge CB2 2XY, UK Corresponding author e-mail:
| | - T. Saheki
- Department of Pharmaco-Biology, University of Bari, Via Orabona 4, 70125 Bari, Italy,
Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Facultad de Ciencias del Medio Ambiente, Universidad de Castilla La Mancha, Toledo, Spain, Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan and The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge CB2 2XY, UK Corresponding author e-mail:
| | - J. Satrústegui
- Department of Pharmaco-Biology, University of Bari, Via Orabona 4, 70125 Bari, Italy,
Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Facultad de Ciencias del Medio Ambiente, Universidad de Castilla La Mancha, Toledo, Spain, Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan and The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge CB2 2XY, UK Corresponding author e-mail:
| | - F. Palmieri
- Department of Pharmaco-Biology, University of Bari, Via Orabona 4, 70125 Bari, Italy,
Departamento de Biologia Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, 28049 Madrid, Facultad de Ciencias del Medio Ambiente, Universidad de Castilla La Mancha, Toledo, Spain, Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan and The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge CB2 2XY, UK Corresponding author e-mail:
| |
Collapse
|
50
|
Carrascosa JM, Molero JC, Fermín Y, Martínez C, Andrés A, Satrústegui J. Effects of chronic treatment with acarbose on glucose and lipid metabolism in obese diabetic Wistar rats. Diabetes Obes Metab 2001; 3:240-8. [PMID: 11520303 DOI: 10.1046/j.1463-1326.2001.00102.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIMS The effect of chronic treatment with acarbose on fasting plasma glucose, insulin, triglyceride, cholesterol and free fatty acid (FFA) concentrations, as well as on the glucose and insulin excursions during oral glucose tolerance test (OGTT), in obese diabetic Wistar (WDF) rats was investigated. METHODS Forty-five mature male WDF rats were randomly distributed to one of the three treatment groups (no acarbose, 20 mg and 40 mg of acarbose/100 g of chow, respectively). After 3.5, 7.5 and 11.5 months, animals were tested for glucose tolerance by means of an OGTT, and their respective metabolic profiles were determined. Control determinations were done in obese and age-matched lean animals before the start of the trial. RESULTS The WDF rats exhibit higher body weight and fasting blood glucose, insulin, triglyceride and cholesterol concentrations compared to lean animals. Moreover, they show marked glucose intolerance as indicated by the glucose and insulin excursions during OGTT. Interestingly, in both treated and untreated animals, a reversion of the hyperglycaemic state as well as an improvement of the glucose tolerance is observed. However, whereas in the group receiving no acarbose this is accounted for by dramatic increases in fasting plasma insulin concentrations and insulin secretion during OGTT (as indicated by the DeltaInsulin area), in rats treated with acarbose the reversion of the diabetic state takes place without increments in hormone concentration. In addition, rats treated with acarbose for 3.5 and 7.5 months show lower plasma triglyceride and FFA concentrations, and the same was observed for cholesterol at the highest dosage of the drug. CONCLUSIONS Chronic treatment with acarbose of WDF rats improves the glycaemic and lipidic control as well as the glucose tolerance, with a lower demand of pancreatic insulin than in untreated rats. This data suggests that the long-term modulation of glucose and insulin excursions after meals improves the insulin sensitivity in this rat strain.
Collapse
Affiliation(s)
- J M Carrascosa
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC), Facultad de Ciencias, Universidad Autónoma, 28049 Madrid, Spain.
| | | | | | | | | | | |
Collapse
|